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Abstract 
Acute myeloid leukaemia (AML) and chronic lymphocytic leukaemia (CLL) 
are common in the elderly. Bruton’s tyrosine kinase (BTK) is an important 
protein that plays a vital role in several signalling pathways including the B 
cell receptor (BCR) and SDF-1α/CXCR4 chemokine signalling pathways. 
Although BTK is a cytoplasmic tyrosine kinase the protein can also found 
in the nucleus. Thus, the nuclear-cytoplasmic shuttling mechanism of BTK 
and BTK-binding protein are proposed in other studies, but BTK’s actual 
role in the nucleus is still unclear. Therefore, the first aspect of this study 
examined BTK and p-BTK in the cytoplasm and nucleus of AML and CLL 
cells. AML and CLL cellular fractionation showed that BTK and p-BTK 
were detected in both cytoplasm and nuclear fractions. Thus, BTK may 
perform important functional roles in their nuclei. The second aspect of this 
study focused on the SDF-1α/CXCR4 signalling pathway which is 
important for AML survival and may control cellular responses through 
BTK. We identified which Gα12 subclasses can couple with CXCR4 
receptor to convey the signalling of BTK, in addition to Gαi–linked 
signalling seen in AML. Results showed CXCR4 was expressed in AML 
and CLL, and that BTK is activated after SDF-1α stimulation.  Therefore, 
our AML and CLL models express functional CXCR4. A gene silencing 
technique was used to identify the roles for Gα12 subclasses of G-proteins 
by knocking down Gα12 or Gα13 via short hairpin RNAs. The Gα12/Gα13 
knockdown cells showed defective SDF-1α-induced migration responses. 
These results suggest that Gα12 and Gα13 can transduce signalling from 
SDF-1α and may be responsible of the activation of BTK in these 
leukaemia cells. In summary, these data reveal important new information 
about the role of BTK in different aspects of leukaemia cell functions and 
provide useful insight into the role of BTK in AML leukaemia. 
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1.1 Leukaemia 
Leukaemia is a disease that defects in proliferation and cell death of 
immature blood cells. They proliferate rapidly and resist to undergo 
apoptosis. According to hematopoiesis, blood cells develop into two 
lineages which are the myeloid lineage and lymphoid lineage as shown in 
figure 1.1. The myeloid cells comprise of macrophage, erythrocyte, 
neutrophil, eosinophil, and dendritic cells while B cells T cells, and natural 
killer (NK) cells derive from the lymphoid linage. Depending on cell type 
and disease progress, leukaemia can be divided into four major group 
which are acute myeloid leukaemia (AML), acute lymphocytic leukaemia 
(ALL), chronic myeloid leukaemia (CML), and chronic lymphocytic 
leukaemia (CLL). In this study, we concentrate on only AML and CLL 
subtype. 
 
According to Cancer Research UK, around 350,000 cases of cancer were 
diagnosed in 2015, with over 160,000 deaths in the same annual period. 
That equates to an overall 50% 10-year survival rate which is improving, 
but far from clinically acceptable. Breast cancer and prostate cancer hold 
the first common incidence cancer in females and males, respectively 
while leukaemia is around the twelfth most common by incidence in both 
genders. Considering leukaemia incidence, there are 3% of leukaemia 
diagnosed from total cancer incidence in 2015. Among all cancer cases, 
less than 1% is acute myeloid leukaemia (AML) diagnosed in 2015. The 
incidence of this leukaemia subtype is increased in older people which 
usually over 75 year old and peaked around 85 to 89 years old. In case of 
chronic lymphocytic leukaemia (CLL), this leukaemia subtype is also 
14 
 
common in older people which the highest incidence is in older than 90 
years old. For acute lymphocytic leukaemia (ALL), there are less than 1% 
of total cancer cases are ALL diagnosed which this subtype common in 
childhood around 0-4 years old. The incidence of another leukaemia 
subtype, chronic myeloid leukaemia (CML), is also less than 1% of total 
cancer cases and CML is also common in older patient which age around 
85-89 years old. All of this information is taken from cancer research UK 
(WWW.cancerresearchuk.org).  
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Figure 1.1 Haematopoietic cell lineage development(Chaplin, 2010). 
The development of lymphoid and myeloid blood cells is originated 
develop from haematopoietic stem cells that generate the common 
progenitor for each cell lineages. The myeloid cell lineage comprises of 
monocyte, neutrophil, eosinophil, basophil, mast cells, megakaryocyte, 
and erythrocyte which derived from common myeloid progenitor. Whereas 
the lymphoid common progenitor cells are developed into B cells, T cells, 
and natural killer (NK) cells which derive from common lymphoid 
progenitor. This figure is adapted from Chaplin, 2010, J Allergy Clin 
Immunol.  
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1.1.1 Acute myeloid leukaemia 
Acute myeloid leukemia is a leukaemia subtype characterized by 
abnormal proliferation of immature myeloid blasts in bone marrow and 
peripheral blood and this type of leukaemia is common in the elderly aged 
over 65 years old. Patient diagnosis for AML is confirmed if more than 
20% of immature myeloid cells are detected in bone marrow and 
peripheral blood (Saultz and Garzon, 2016, Dohner et al., 2010). AML is 
the most common type of leukaemia among subgroups in United States, 
2017 (Siegel et al., 2017). The population of AML cells is heterogeneous 
which contains variable genetic background including chromosome 
abnormality, several gene mutations that lead to aberration of gene 
expression, and abnormality of miRNA expression (Kumar, 2011).  
 
Chromosomal inversion, translocation, and deletion can be found in AML 
cells, however there are common abnormalities in cytogenetic alteration 
where the abnormality leads to oncofusion proteins, including PML-RARα 
from t(15;17), AML1-ETO from t(8;21), CBFβ-MYH11 from inv(16), and 
MLLs rearrangement from 11q23 (Martens and Stunnenberg, 2010). Gene 
mutations can be found in AML patients with normal cytogenetics which 
the gene mutation of AML blast can be categorized into three classes. The 
disease progression needs more than one class of mutation to develop 
into leukaemia according to two hit model (De Kouchkovsky and Abdul-
Hay, 2016). Class I involves signalling pathways that enhance proliferation 
and survival of blasts and FLT3-ITD, K/NRAS, TP53, and c-KIT are 
classified into this class (Kumar, 2011, Estey, 2016, De Kouchkovsky and 
Abdul-Hay, 2016). The mutation of differentiation regulated gene, NPM1 
and CABPA, are classified into class II mutations. Epigenetic regulation 
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gene mutation including DNMT3A, TET2, IDH1, and IDH2 are classified 
into class III (De Kouchkovsky and Abdul-Hay, 2016, Dombret, 2011). The 
different mutations show distinct outcomes for prognostic treatment. Thus 
the classification of AML blasts at diagnosis is important for treatment. 
 
There are several criteria for AML classification including blast 
morphology, genomic abnormality, or outcome of treatment. The French 
American British (FAB) classification is based on morphology and 
development which can be divided into 9 stages from M0-M7 as shown in 
Table 1.1 (Bennett et al., 1976). In addition, AML is also classified by 
genetic alteration background according to World Health Organization 
classification shown in Table 1.2. AML morphology and chromosome 
alteration are not the only criteria for AML classification, the prognostic risk 
is also used as a criteria for classification into favourable, intermediate I 
and II, and adverse (Saultz and Garzon, 2016). 
 
Since, AML harbours mutations that effect aberrant signalling pathways 
and epigenetics, signalling protein targeted therapy in these pathways is 
an interesting candidate for AML treatment after several studies have 
shown interfering with these pathways affects AML survival. As FLT3-ITD 
mutation is found in AML blast, FLT3 inhibitors are considered to be 
potential targeted drugs where the first and the second generation of FLT3 
inhibitors have already been applied in clinical trials (De Kouchkovsky and 
Abdul-Hay, 2016). The BTK inhibitor, ibrutinib, reduces viability of patient 
AML blasts, in addition, ibrutinib also inhibits pro-survival signal-induced 
proliferation and adhesion to BMSCs (Rushworth et al., 2014). 
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Furthermore, there are epigenetic-targeted drugs which are also 
undergoing clinical trials (Chen et al., 2010, Sun et al., 2018). 
 
 
 
 
Table 1.1 Acute myeloid leukaemia classification according to 
French-British-America (FAB) (Kumar, 2011). 
The FAB classification is based on AML morphology. AML cells are 
divided into 9 subgroups. This table is adapted from Kumar, C. C. Genes 
Cancer (2011) doi: 10.1177/1947601911408076. 
 
 
 
 
 
 
  
AML subtypes Morphology 
AML-M0 Undifferentiated acute myeloblastic leukaemia 
AML-M1 Acute myeloblastic leukaemia with minimal maturation 
AML-M2 Acute myeloblastic leukaemia with maturation 
AML-M3 Acute promyelocytic leukaemia 
AML-M4 Acute myelomonocytic leukaemia 
AML-M4 Acute myelomonocytic leukaemia eosinophilia 
AML-M5 Acute monocytic leukaemia 
AML-M6 Acute erythroid leukaemia 
AML-M7 Acute megakaryoblastic leukaemia 
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Classification Genetic Abnormalities 
AML with recurrent genetic abnormalities AML with t(8;21)(q22;q22.1);RUNX1T1 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 
t(6;9)(p21.3;q23.3);MLLT3-KMT2A 
t(6;9)(p23;q34.1);DEK-NUP214 
inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM 
BCR-ABL1 provisional entity 
Mutated NPM1 
Biallelic mutation of CEBPA 
Mutated RUNX1 provisional entity 
APL with PML-RARA 
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1 
AML with myelodysplasia-related changes  
Therapy-related myeloid neoplasm  
AML, not otherwise specific AML with minimal differentiation 
AML without maturation/AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic/monocytic leukaemia 
Pure erythroid leukaemia 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma  
Myeloid proliferations related to Down syndrome Transient abnormal myelopoiesis  
Myeloid leuakemia associated with Down syndrome 
Table 1.2 AML classifications according to World health Organization (Arber et al., 2016). 
The WHO classification of AML is based on chromosomal abnormality. This table is modified from Arber, D.A., Orazi, A. et al, Blood (2016) doi: 10.1182/blood-2016-03-643544 
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1.1.2 Chronic lymphocytic leukaemia 
Chronic lymphocytic leukaemia is a non-Hodgkin lymphoma which shows 
high incidence in elderly with median age at 75 years old (Hallek et al., 
2018). CLL is diagnosed by accumulation of CD5 positive cells in blood, 
bone marrow, and lymphoid organs and presence of lymphocytosis and 
lymphadenopathy (Hallek et al., 2018). CLL cells are more mature than 
AML subtypes but the problem of this subtype of leukaemia is apoptosis 
resistance that leads to accumulation of immature lymphoid cells. This 
leukaemia subtype can be developed from many risk factors including 
family genetic background and external stimuli exposure such as smoking, 
farming experience, and infection (Slager et al., 2014). CLL is also a 
heterogeneous disease that several chromosomal aberrations and genetic 
abnormalities are involved. The abnormalities of chromosome structure 
are reported including trisomy12, and deletion at chromosome 6q, 11q, 
13q, or 17p (Shahjahani et al., 2015). Moreover, mutations involving 
signalling pathways, epigenetics, and micro-RNA processing are also 
found in CLL patients such as TP53, NOTCH1, and MYD88. The gene 
mutation, prognostic markers, and mutation status of Ig heavy chain 
variable region (IGHV) are also related to disease outcome as well as 
disease progression and survival rate of CLL patients (Hallek et al., 2018). 
The expression of surface markers are characterized and compared the 
expression with normal B cells which BCR receptor (IgM and IgD) and Igα 
are lower express while CD5, CD19, CD20, and CD23 are vice versa. 
(Herman et al., 2010, Matutes et al., 1994a, Matutes et al., 1994b). In 
order to apply appropriate treatment for patients, the Rai and Binet CLL 
systems are used for stage characterization. These two systems were 
published in 1975 and 1981 and are based on patient examination and 
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laboratory testing (Rai et al., 1975, Binet et al., 1981, Rai and Jain, 2016, 
Hallek et al., 2018). According to the Rai system, CLL is divided into 3 
groups which are low risk (stage 0), intermediate risk (stage I-II), and high 
risk (stage III-IV) while CLL is classified into 3 groups according to Binet 
system (Rai and Jain, 2016, Gribben, 2010).  
 
Chemotherapy has been developed as a standard treatment for many 
years which starts with monotherapy using alkylating agents, to 
combination chemotherapy, but many chemotherapeutic drugs are not 
suitable for the treatment of some patients considering their high toxicity 
(Rai and Jain, 2016). Thus, targeted therapy is an interesting candidate 
especially drugs targeting the B cell receptor (BCR) signalling pathway 
and microenvironment because these pathways provide survival 
supporting signals beneficial to CLL and the aberrant activation of these 
signalling pathways is reported in CLL progression. 
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Stage Clinical features 
0 (low risk) Lymphocytosis in blood and marrow only 
I-II (intermediate 
risk) 
Lymphadenopathy, splenomegaly +/- 
hepatomegaly 
III-IV (high risk) Anemia, thrombocytopenia 
 
Table 1.3 Rai classification system of chronic lymphocytic leukaemia 
(CLL) (Gribben, 2010). 
This table is adapted from Gribben, J. G. Blood (2010) doi: 10.1182/blood-
2009-08-207126 
 
 
Group Clinical features 
A Fewer than 3 areas of lymphadenopathy; no 
anemia or thrombocytopenia  
B More than 3 involved node areas; no anemia or 
thrombocytopenia  
C Hemoglobin < 100 g/L 
Platelets < 100x10 g/L 
 
Table 1.4 Binet classification of chronic lymphocytic leukaemia (CLL) 
(Gribben, 2010). 
This table is adapted from Gribben, J. G. Blood (2010) doi: 10.1182/blood-
2009-08-207126 
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1.2 Chemotherapeutic treatment for haematological malignancies 
Chemotherapy is the first choice treatment for blood cancer. Some of 
chemotherapeutic drugs have already approved by FDA while lots of them 
are undergoing clinical trials. The new drugs have been developed for the 
better outcome. Chemotherapeutic drugs can be prescribed as 
monotherapy or in combination. The treatment strategy depends on 
patient’s health and genetic background.  Below is a table 1.5 that outlines 
the different chemotherapies used among different blood cancers, and the 
year they were introduced and added to the clinician’s drug arsenal. 
Hodgkin’s 
Lymphoma 
Non-Hodgkin’s Lymphoma Myelomas 
Carmustine – 1947+ 
Prednisone – 1950 
Doxorubicin – 1950s 
Cyclophosphamide – 
1954 
Lomustine – 1954+ 
Vincristine – 1963 
Bleomycin – 1966 
Dacarbazine – 1975 
Chlorambucil – 1977 
Brentuximab – 2011 
(CD30/TNFRSF8 
mAb) 
Methotrexate – 1947 
Carmustine – 1947+ 
Prednisone – 1950 
Doxorubicin – 1950s 
Cyclophosphamide –1954 
Lenalidomide – 1957+ 
Cytarabine – 1959 
Bendamustine – 1963 
Vincristine – 1963 
Bleomycin – 1966 
Chlorambucil – 1977 
Plerixafor – 1987 (CXCR4i) 
Romidepsin, Vorinostat, 
Belinostat – 1994 (HDACi) 
Bortezomib – 1995 (26Si) 
Denileukin Diftitox – 1996 
(IL-2R mAb diphtheria tox) 
Rituximab – 1998 (CD20 
mAb) 
Ibrutinib – 2007 (BTK TKI) 
Carmustine – 1947+ 
Prednisone – 1950 
Doxorubicin – 1950s 
Cyclophosphamide – 
1954 
Thalidomide – 1957 
Lenalidomide – 1957+ 
Pomalidomide– 1957+ 
Pamidronate – 1976 
(Bisphosphonate) 
Zoledronate – 1976+ 
(Bisphosphonate) 
Plerixafor – 1987 (CXCR4 
inhibitor) 
Bortezomib – 1995 (26S 
proteasome inhibitor) 
Carfilzomib – 1995+ (26S 
proteasome inhibitor) 
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Idelalisib – 2008 (PI-3-Kδi) 
Brentuximab – 2011 
(CD30/TNFRSF8 mAb) 
 
ALL AML CLL CML 
Methotrexate – 1947 
Sydney Farber 
Prednisone – 1950 
Daunorubicin – 
1950s 
Doxorubicin – 1950s 
Cyclophosphamide 
– 
1954 
Clofarabine – 1957 
Cytarabine – 1959 
Vincristine – 1963 
Mercaptopurine – 
1967 
Imatinib (Gleevec) – 
1992 
Dasatinib – 1992+ 
Ponatinib – 1992+ 
Blinatumomab – 
2014 (CD3/CD19 
mAb) 
Arsenic Trioxide – 
1920 
Daunorubicin – 
1950s 
Idarubicin – 1950+ 
Doxorubicin – 1950s 
Mitoxantrone – 
1950s 
Cyclophosphamide 
– 
1954 
Cytarabine – 1959 
Vincristine – 1963 
Mustargen – 1947+ 
Prednisone – 1950 
Cyclophosphamide – 
1954 
Chlorambucil – 1977 
Bendamustine – 1963 
Fludarabine – 1968 
Alemtuzumab – 1983 
(CD52) 
Rituximab – 1998 
(CD20 mAb) 
Ofatumumab – 1998+ 
(CD20 mAb) 
Obinutuzumab – 
1998+ 
(CD20 mAb) 
Ibrutinib – 2007 
(BTK TKI) 
Idelalisib – 2008 
(PI-3-Kδ inhibitor) 
 
Mustargen – 
1947+ 
Cyclophosphamide 
– 
1954 
Busulfan – 1959 
Cytarabine – 1959 
Imatinib (Gleevec) 
– 
1992 
Dasatinib – 1992+ 
Ponatinib – 1992+ 
Omacetaxine – 
2011 
(translation 
inhibitor) 
 
Table 1.5 Chemotherapeutic drugs for haematological malignancies. 
This table shows variety of drugs that use for blood cancer treatment. 
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1.2.1 Chemotherapy treatment for acute myeloid leukaemia (AML) 
The chemotherapeutic treatment for AML is divided into two stages which 
are induction and consolidation. The induction is the first treatment after 
patient is diagnosed as AML which aims for the clearance the circulating 
leukaemic cells from the blood and the bone marrow. The standard 
treatment composes of high dosage treatment with 60 mg/m2 of 
daunorubicin for 3 days and 100-200 mg/m2 of cytarabine for another 7 
days (Dohner et al., 2015). Once induction treatment has finished, 
consolidation starts in order to prevent relapse which due to the presence 
of resisted AML clone from induction therapy. In consolidation treatment, 
patient is treated with intermediate dose of cytarabine or transplantation 
(Dohner et al., 2015). However, these two main chemotherapy regiments 
cause unpleasant side effects for unfit or elderly patients. Therefore, the 
targeted therapies are considered as an alternative treatment for unfit 
patients (Short and Ravandi, 2016). FLT3 inhibitors, epigenetics regulator 
inhibitors, nuclear exporter inhibitor, and cell cycle regulator inhibitors are 
undergoing clinical trials and be considered as novel drugs for AML 
treatment (Saultz and Garzon, 2016, Dohner et al., 2015). 
 
1.2.2 Chemotherapy for chronic lymphocytic leukaemia (CLL) 
In the beginning, the alkylating agents (Chlorambucil) and purine analogs 
(Fludarabine, Pentostatin, and Cladribine) have been used as 
monotherapy drug for CLL diagnosed patients. Then the combination of 
fludarabine, cyclophosphamide, and rituximab (FCR) is developed as a 
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frontline chemotherapy treatment for the fit group of patient which the 
combination of bendamustine and rituximab is more preferable in elderly 
patient. Beside rituximab, the others anti-CD20 antibodies have been 
developed which are ofatumumab and obinutuzuman (Jamroziak et al., 
2017, Hallek, 2017). Overall, the choice of drugs and treatment strategies 
are selected based on genetic background, patient’s health condition, and 
outcome of the first treatment. As CLL is common in old patient and 
chemotherapeutic drugs have non-suitable side effects, the alternative 
drugs that have high efficiency with lesser side effects have been 
developed. The inhibitors of proteins that play an important role in 
signalling pathway and protein that involved in apoptosis mechanism are 
considered as alternative drugs for unfit patient. 
 
1.2.3 Chemotherapy in acute lymphocytic leukaemia (ALL) 
Acute lymphocytic leukaemia (ALL) is leukaemia subtype that common in 
childhood which this subtype is also diagnosed in adult. The treatment in 
adult ALL shows lower successful rate than the rate in children (Jabbour et 
al., 2010). The treatment comprises of three steps which are remission, 
consolidation, and maintainance in ALL diagnosed patients. The induction 
treatment schedule starts with cyclophosohamide then follow by other 
drugs including daunorubicin, vincristine, L-asparaginase, and prednisone 
(Terwilliger and Abdul-Hay, 2017). The modified regiment is considered for 
elderly and unfit patient (Wolach et al., 2017). In addition to the main 
regimen, CNS prophylaxis by using radiation, systemic chemotherapy, or 
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intrathecal chemotherapy, is applied in ALL diagnosed patient since CNS 
recurrence has been reported (Jabbour et al., 2010). However the better 
drug and treatment strategy are undergoing development.  
 
1.2.4 Chemotherapy in chronic myeloid leukaemia (CML) 
CML diagnosed patients were treated with Busalfan and Hydroxyurea then 
these chemotherapeutic drugs were replaced with imatinib which is 
tyrosine kinase inhibitor. Imatinib shows favourable outcome for 
Philadelphia positive mutation (Baccarani et al., 2014, Cortes et al., 1996). 
Interferon-alpha is  also used as an option for CML diagnosed patient in 
combination with imatinib (Jabbour and Kantarjian, 2016). There are four 
front line tyrosine kinase inhibitors are approved by FDA to apply in CML-
chronic phase which are imatinib, dasatinib, nilotinib, and bosutinib 
(Jabbour and Kantarjian, 2018). The stem cells transplantation shows 
good treatment outcome after chemotherapeutic relapse with limited age 
of patient (Baccarani et al., 2014).  
 
In summary, chemotherapeutic drugs show several side effects and some 
of drugs are only suitable to the specific group of patients which depends 
on age and genetic background of patient in common with all subtype of 
leukaemia. Therefore, the drugs are still developing in order to improve 
specificity and minimize side effects. Most of the new drugs are designed 
based on the better understanding of molecular pathogenesis to inhibit the 
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specific protein in aberrant signalling pathway or reverse some mutations 
in each type of leukaemia. 
 
1.3 Bruton’s tyrosine kinase 
1.3.1 Bruton’s tyrosine kinase biology 
Bruton’s tyrosine kinase is non-receptor tyrosine kinase which belongs to 
the Tec family of tyrosine kinases and share the same family with TEC, 
ITK/EMT/Tsk, BMX, and TXK/RLK (Mano, 1999). BTK structure is 
composed of five domains: which are the Pleckstrin homology (PH), Tec 
homology (TH), SRC homology domain 3 (SH3), SRC homology domain 2 
(SH2), and SRC homology domain 1 (SH1) also known as the kinase 
domain, as arranged from the N-terminus to C-terminus as shown in 
Figure 1.1 (Hendriks et al., 2014, Lindvall et al., 2005).  
 
This protein was originally identified in B cells as a signalling molecule in 
the B cell signalling pathway (BCR), nevertheless BTK is not only 
expressed in B cells, but this protein is also found in other hematopoietic 
cells, including spleen, bone marrow, lung, and pancreas but not T cells 
and plasma cells (Vihinen et al., 2000). In the 1980s, BTK was reportedly 
mutated to cause severe X-linked agammaglobulinemia (XLA) in humans 
and less severely in xid mice. BTK is conserved throughout evolution. 
Since BTK plays an important role in B cells, BTK mutation may cause the 
defect in B-cell development which leads to X-Linked 
agammaglobulinemia (XLA) in humans and X-linked immunodeficiency 
(XID) in mice. In humans, B cell development is arrested at the transition 
stage from pre B cell to mature B cell. In human, XLA patients are 
susceptible to recurring infection since BTK in human causes almost 
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complete absence of mature B cells which leads to a lack of circulating 
antibody and defect in T cell dependent immune response (Khan et al., 
1995). Since mutation BTK is not important in the early stage of B cell 
development and mutation is found in later stage, therefore circulating B 
cells in XID are more mature than in XLA and this deficiency is less severe 
than XLA in humans, even if BTK is deleted in mice. Although BTK 
mutation causes milder effect in mice, xid mice shows low amount of 
IgM/IgD B cells, circulated IgM and IgG3, and defect in response to TI-II 
antigen and other activation signals (Khan et al., 1995).  
 
 
 
 
 
 
Figure 1.2 Bruton’s tyrosine kinase structure. 
Bruton’s tyrosine kinase (BTK) composes of five domains and the auto- 
and trans-phosphorylation site are embedded in SH3 and SH1 (kinase 
domain), respectively. This figure is adapted from (Hendriks et al., 2014). 
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1.3.2 Subcellular distribution of Bruton’s tyrosine kinase  
BTK expression is mainly in the cytoplasm, but can also be found in other 
cellular compartments under specific circumstances. BTK translocates to 
the plasma membrane and binds to PIP3 after receptors stimulation (Nore 
et al., 2000). The fully phosphorylated BTK regulates cell response by 
transducing the signal information through a downstream cascade. There 
is a small amount of BTK found in nucleus and BTK contains the nuclear 
localization signal (NLS) which is a transport signal for Exportin 1 
(Mohamed et al., 2000). The SH3 domain is important for nuclear export 
since BTK is retained in nucleus of SH3 mutant cells, and the SH3 domain 
is proposed to be a binding site of Liar. The BTK-Liar complex is 
transported to the cytoplasm using the carrier protein, Expotin 1 
(Mohamed et al., 2000, Gustafsson et al., 2012). Other studies also 
propose the nucleocytoplasmic shuttle mechanism of BTK and its binding 
protein partner which prove nucleus-cytoplasm shuttle and possibility that 
BTK plays an important role in nucleus. BAM11 and Liar are identified as 
BTK binding protein and may involve in nucleus-cytoplasm travelling of 
BTK (Kikuchi et al., 2000, Hirano et al., 2004, Gustafsson et al., 2012, 
Gustafsson et al., 2017).  
 
The B cell regulator of Ig heavy chain transcription (Bright) is proposed as 
a putative BTK binding partner and BTK is needed to form a DNA binding 
complex (Webb et al., 2000, Rajaiya et al., 2005). Although, the role of 
BTK itself in the nucleus still remains to be discovered, however there are 
several studies showing that BTK regulates nuclear proteins such as NF-
κB, transcription factor II-I (TFII-I), and Bright. So, this data may imply the 
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possibility that BTK has a role in nucleus. Nevertheless, we need more 
evidence to prove this hypothesis.  
 
1.3.3 Bruton’s tyrosine kinase and relevant signalling pathways 
As BTK is a player in several signalling pathways, it can act as a linker 
protein activated by various receptors to control diverse cellular 
responses. We explore only two of these signalling pathways here that 
relate to this study.  
 
1.3.3.1 B cell receptor (BCR) signalling pathway 
The BCR signalling pathway controls B cell survival and proliferation, 
where the B cell receptor comprises a surface immune receptor 
associated with Igα/Igβ or CD79A/CD79B heterodimer with 
immunoreceptor tyrosine based activation motifs (ITAMs), and co-receptor 
(CD19). As BTK was firstly identified in XLA and XID where BTK mutation 
affects B cell development, the participation of BTK in BCR is well 
characterized in normal B cells and B cell malignancies.  
 
Once BCR is activated by IgM binding, there are two situations which may 
occur at the same time. The Src family protein tyrosine kinase, LYN 
phosphorylates ITAMs and CD19 which recruits SYK and PI3K binding at 
ITAMs of the Igα/Igβ heterodimer and CD19, respectively (Hibbs and 
Dunn, 1997, O'Rourke et al., 1998). BTK is recruited to plasma membrane 
and anchored to the membrane via the PH domain and the second 
messenger, PIP3 which is generated from PI3K (Saito et al., 2001). The 
membrane bound BTK is fully activated by both SYK phosphorylation at 
Y551 and auto-phosphorylation at Y223. The activated p-BTK transduces 
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signals to control cellular responses via several downstream signalling 
proteins by phosphorylates phospholipase C-γ2 (PLCγ2), which is a direct 
substrate of BTK (Kurosaki, 2002). The PLCγ2 is a Ca2+ regulator via PIP3 
generated from PIP2 and this pathway lead to activation of nuclear factor 
of activated T cells (NFAT) (Pal Singh et al., 2018). In parallel, another 
secondary messenger which also generated from PIP3, diacylglycerol 
(DAG) activates protein kinase C beta (PKCβ). The p-PKCβ can control 
two important downstream effector molecules which are ERK1/2 via Ras-
dependent phosphorylation and NF-κB (Pal Singh et al., 2018). The BCR 
signalling pathway is shown in Figure 1.2.  
 
1.3.3.2 SDF-1α/CXCR4 chemokine signalling pathway  
SDF-1α/CXCR4 is involved in leukaemia pathogenesis by providing the 
survival support signal and protecting leukaemia cells from drug-induced 
apoptosis by induced CXCR4 receptor expressed, stimulating cells to 
migrate towards SDF-1α and retain inside bone marrow 
microenvironment. BTK is reported to be involved in this pathway and BTK 
inhibition shows effects from SDF-1α/CXCR4 interference. As shown in 
Figure 1.4, CXCR4 transduces signalling to BTK via G protein subunit and 
links BCR signalling pathway and SDF-1α/CXCR4 by using BTK as a 
linker molecule. 
 
There are studies showing that BTK can receive signalling from CXCR4 
receptor and transduce signalling to regulate migration and adhesion in 
response to SDF-1α in mouse and human B cells. In addition, BTK 
deficient B cells also show defects in homing to lymphoid organs (de 
Gorter et al., 2007, Ortolano et al., 2006). In CLL, BTK inhibition using 
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ibrutinib blocks pro-survival signal from NLCs and diminishes cell survival 
and migration induced by CXCL12 (SDF-1α) and CXCL13 (Ponader et al., 
2012). Even though the role of BTK in AML is not well understood, there 
are a few studies that show involvement between BTK and CXCR4 
receptor in this leukaemia subtype. BTK inhibition reduces SDF-1α 
induced cell migration in AML patient samples (Zaitseva et al., 2014). 
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Figure 1.3 B cell receptor (BCR) signalling pathway (Pal Singh et al., 
2018). 
This figure shows BTK is one of several participants in B cell receptor 
signalling pathway.  BTK is recruited to plasma membrane and activated 
by SYK. The phosphorylated BTK activates downstream signalling 
molecule which transduce the signalling in order to response to stimuli. 
This figure is adapted from Pal Singh et al. Molecular Cancer (2018) doi: 
10.1186/s12943-018-0779-z. 
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Figure 1.4 Role of Bruton’s tyrosine kinase in B cell receptor and 
SDF-1α/CXCR4 signalling pathway (Pal Singh et al., 2018). 
BTK participates in SDF-1α/CXCR4 signalling pathway in addition to BCR 
signalling pathway and act as a linker molecule to link each signaling 
pathway into the signalling network as shown in this figure. This figure is 
adapted from Pal Singh et al. Molecular Cancer (2018) doi: 
10.1186/s12943-018-0779-z. The Creative Commons License 
(http://creativecommons.org/licenses/by/4.0/) 
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1.3.4 Role of BTK in chronic lymphocytic leukaemia  
As BTK controls cell survival and proliferation, aberrant p-BTK may lead to 
an imbalance of cell proliferation related diseases, especially cancers. In 
CLL, the participation of BTK is well characterized compared to its role in 
AML. The difference in BCR signalling responses has been reported in 
normal B cells and CLL including BCR and co-receptor density and variety 
in downstream signalling protein activation (Woyach et al., 2012). In CLL, 
BTK mRNA expression is elevated compared to normal B cells and BTK 
expression at protein level is varied among CLL patients without 
correlation to with other disease-related factors (Herman et al., 2011). The 
important roles for BTK were proven by investigation into the effect of BTK 
inhibition on the downstream cellular responses in several studies. Other 
proteins proposed as downstream molecules were also investigated after 
BTK inhibition. The phosphorylation of ERK1/2 decreased compared to 
untreated, and DNA-binding activity of NF-κB was reduced after CLL 
patient samples were treated with PCI-32765 (Herman et al., 2011). Since 
BTK is involved in BCR signalling pathways that control cell survival and 
proliferation, several studies showed BTK inhibition diminished these two 
cellular responses (Ponader et al., 2012, Herman et al., 2011).  
 
Since, BTK can transduce signals from several receptors and the role of 
BTK is not restricted to BCR signalling, the effects of BTK inhibition on 
CLL survival and other effector responses was investigated in other 
pathways including microenvironment-involved signalling pathways. PCI-
32765 reduced the effect of cytokine supporting survival signals that 
provided from TNF-α, IL-6, IL-4, CD40L, BAFF, and co-culture with 
stromal cells and induced apoptosis in co-treatment. (Herman et al., 
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2011). There is evidence to show BTK is also critical in the SDF-
1α/CXCR4 axis which Ibrutinib treatment interferes in CLL. Ibrutinib 
treatment effects CXCR4 receptor density and downstream effectors 
which cause CLL cells egress from secondary lymphoid organs into the 
blood circulation (lymphocytosis)(Chen et al., 2016). 
 
1.3.5 Role of BTK in acute myeloid leukaemia 
Although participation of BTK is reported in B cells and B cell 
malignancies, the supporting evidence that BTK may be important in AML 
is expanded in AML leukaemia subtype research even though roles of 
BTK in AML are not well understood. The proposed role of BTK in this 
leukaemia subtype is emphasized in survival signals that are provided 
from bone marrow microenvironment. BTK and p-BTK is also detected in 
AML patients with variation among patients as shown in CLL. Moreover, 
BTK itself and other downstream proteins of BTK are activated after SDF-
1α treatment, moreover, genetically BTK inhibition affects AML cell 
migration toward SDF-1α (Rushworth et al., 2014, Zaitseva et al., 2014). 
Since BTK is a linker molecule, the aberrant mode of BTK and p-BTK also 
affects other pathways. As BTK may be important in AML as well as in 
CLL, BTK inhibitors are interesting therapeutic treatments. We need more 
information to understand the roles of BTK in AML. 
 
1.4 SDF-1α/CXCR4 signalling pathway  
CXCR4 is a seven transmembrane G-protein-coupled receptor firstly 
identified as a co-receptor for HIV-1 T-tropic virus infection (Feng et al., 
1996). The stromal cell-derived factor (SDF-1α) also known as CXCL12 is 
a chemotactic cytokine (chemokine) belonging to the CXC group. SDF-1α 
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was firstly identified in murine bone marrow stromal cells (Teicher and 
Fricker, 2010, Tashiro et al., 1993). The SDF-1α is encoded from the 
same gene as another isoform, SDF-1β, by splicing (Shirozu et al., 1995). 
SDF-1α induces directional migration of CXCR4 expressing cells towards 
SDF-1α. In normal circumstances, SDF-1α/CXCR4 is responsible for 
several processes including haematopoiesis, germ cell development, 
neurogenesis, cardiogenesis and vascular formation (Nagasawa, 2014). 
SDF-1α/CXCR4 induced cell mobilization is important for cancer cells 
because the signalling pathway is necessary for processes in normal cells 
and those dysregulated in cancer development such as preventing 
apoptosis and promoting migration. 
 
In general, SDF-1α/CXCR4 signalling pathways play a vital role in normal 
cells, however cancer cells can take advantage of this pathway to support 
survival, proliferation, and other effects. The SDF-1α/CXCR4 signalling 
pathway is one of the pathways controlling chemotactic cell migration, 
adhesion, and cell survival. This pathway is crucial in the 
microenvironment that provides supportive sustenance for cell survival 
and to prevent drug-induced apoptosis. As such, CXCR4 can be used as a 
prognostic marker in leukaemia. 
 
1.5 G-protein-coupled receptor and Heterotrimeric G proteins  
The G-protein-coupled receptor (GPCR) is the largest class of human 
membrane receptors with each possessing seven transmembrane-loops in 
their structure (Kobilka, 2007). Once a GPCR is activated with a specific 
ligand, signalling conveys to downstream proteins via a heterotrimeric G 
protein linked to the cytoplasmic tail of the receptor (Simon et al., 1991). 
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The heterotrimeric comprises of Gα, Gβ, and Gγ subunits. The Gα subunit 
can be classified into Gαi, Gαs, Gαq, and Gα12 based on amino acid 
similarity with each subclass linked with different surface receptors and 
transduce signalling to diverse effector proteins as shown in Figure 1.4 
(Simon et al., 1991). The activation of heterotrimeric G proteins is 
regulated by guanine nucleotide triphosphate (GTP) binding with the Gα 
subunit. In its resting state, Gα, Gβ, and Gγ are together in a 
heterotrimeric form with Gα bound to GDP. In activation, ligand binding 
induces receptor conformational change and GDP is replaced with GTP 
and the heterotrimeric G protein becomes active. The G protein complex 
dissociates into Gα-GTP and Gβγ which lead to downstream pathway 
activation. Once GTP-bound Gα protein is hydrolysed to GDP, the 
heterotrimeric structure reforms and returning to an inactive state (Kamp et 
al., 2016). The occupancy of Gα with GTP or GDP is controlled by guanine 
nucleotide exchange factors (GEFs), GTPase-activating protein (GAPs), 
and guanine nucleotide dissociation inhibitor (GDIs) as shown in Figure 
1.5 (Siderovski and Willard, 2005). 
 
GPCRs can transduce information from ligand to more than one class of 
Gα subunit which increases the variety of cellular responses as different 
classes of Gα regulate distinct effector responses. The Gαs subclass 
activates adenylyl cyclase and cAMP while Gαi or pertussis toxin sensitive 
G protein inhibits adenylyl cyclase and regulates ion channel. The Gαq 
subunit controls Ca2
+ mobilization via PLCβ, IP3 and DAG generation 
which in turn controls Ca2
+ efflux and activates PKC, respectively (Neves 
et al., 2002). Although the Gα12 subclass is not fully understood, the study 
of this subclass is still growing and Gα12 has been reported to bind BTK, 
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Ras-GAP, ERK5 and JNK (Jiang et al., 1998, Neves et al., 2002). Another 
member of this subclass, Gα13 is reported to transduce signals to GTPase 
Rho and PI3K pathways (Neves et al., 2002, Shi and Kehrl, 2001). In 
addition, studies show GPCRs can couple with more than one Gα 
subclass and the same receptor can be linked with different Gα subunit in 
different cell line. The chemokine signalling pathway SDF-1α/CXCR4 can 
transduce signalling from SDF-1α to downstream proteins through both 
Gαi and Gα12 in hematopoietic cells and breast cancer respectively (Tan et 
al., 2006, Zaitseva et al., 2014, Yagi et al., 2011). This information 
demonstrates the complexity of GPCRs and cellular responses through G 
protein regulation which need to be investigated in different cell lines. 
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Figure 1.5 Diversity of G protein signal transduction. 
GPCR signalling is initiated from external stimuli and signalling information 
is transduced downstream via G protein coupled receptor containing an α 
subunit and βγ heterodimer. The diversity of GPCR signal transduction is 
associated to the differenced in the seven-transmembrane receptor. G 
protein coupled receptor can be activated with various types of stimuli. Gα 
subunit is divided into four subclasses resulting in the activation of 
different signaling molecules. This figure is  adapted from (Dorsam and 
Gutkind, 2007) 
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Figure 1.6 The regulation of Gα subunit (Kamp et al., 2016). 
The active and inactive state of G proteins is controlled by GTP/GDP 
binding with Gα protein.  This figure is adapted from (Kamp et al., 2016) 
doi: 10.3390/ijms17010090.  
 
 
1.6 Lentiviral vector and short hairpin RNA-based gene silencing 
technology 
Lentiviruses are single stranded positive RNA viruses which are classified 
into Retroviridae family, Retrovirus genus (Sakuma et al., 2012). The 
lentiviral vectors are constructed based on HIV-1. Lentiviral technology 
takes advantage of the retrovirus life cycle as the viral genome is 
integrated into host chromosomes which is beneficial for long term 
expression of the transgene. Lentiviruses are capable of infecting a wide 
variety of cell types including dividing and non-dividing cells including cells 
of a hematopoietic lineage (Wiznerowicz and Trono, 2005).  
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Lentiviral vectors have been modified to increase biosafety and enhance 
transfection performance. As a safety consideration, only the necessary 
viral genes for viral capsid (gag), transcriptional enzyme (pol), and viral 
envelope (env) are embedded in the lentiviral vector while the virulence 
involved accessary genes are removed (Blesch, 2004, Kim et al., 1998).  
 
In order to increase biosafety and transfection efficiency, the viral genes 
are separated into different vectors and the lentiviral env gene is changed 
to another viral env gene. The lentiviral vectors are developed into several 
generations of vector (Figure 1.7). In the first and second generation 
lentiviral vector, structure and packaging encoded genes are separated 
into 2 plasmids and the transgene is placed on another plasmid along with 
5’ LTR, 3’ LTR region and viral accessory genes (vif, vipu, vpr, and nef) 
are deleted in the second generation. In the third generation, there are 
three main modifications. The rev is placed solely on another plasmid, 
separated from the packaging plasmid. The 5’ and 3’ LTR are modified in 
the transgene plasmid in to minimize the opportunity of creating 
replication-competent lentivirus. The promotor of the transgene vector is 
changed to a CMV promotor (Sakuma et al., 2012).  
 
Gene silencing is a useful application to study the importance of an 
interesting protein or to dissect signalling pathways. Short hairpin RNA 
(shRNA) mediated gene silencing provides long term gene suppression. 
The structure of shRNA comprises an siRNA sequence, loop region, 
complementary siRNA sequence, and terminator (Manjunath et al., 2009). 
As shown in Figure 1.7, the process of shRNA mediated gene silencing 
starts from lentivirus production of shRNA containing lentiviral particles in 
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packaging cells. HEK293T cells are usually used as a factory for lentiviral 
production (Manjunath et al., 2009). Once targeted cells are transfected 
with shRNA containing viruses, the transgene vector is integrated into the 
host genome and the shRNA is produced and processed by Drosha in the 
nucleus. The shRNA that serves as siRNA precursor is transported to the 
cytoplasm and the loop part is cut by Dicer to create siRNA. The anti-
sense strand is loaded into RISC and binds to complementary regions in 
the target mRNA. Gene suppression may result from mRNA degradation 
or translation suppression. Since shRNA integrates into the host genome, 
the siRNA is constitutively expressed and target mRNA is stably 
suppressed (Torrecilla et al., 2014).  
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Figure 1.7 The development of the lentiviral vector system.  Figure 
adapted from (Sakuma et al., 2012). As a safety consideration, the 
lentiviral genes are separated to different plasmids. The first generation, 
the necessary viral genes are separated into two plasmids (A). The 
accessory genes (vif, vpu, vpr, and nef) are removed from plasmids in the 
second generation (B). The third generation plasmid, rev is separated into 
its own plasmid therefore this generation contain four plasmids. 
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Figure 1.8 Short hairpin RNA containing lentivirus production.  Figure 
adapted from (Manjunath et al., 2009).  Shown are the structural lentivirus 
plasmids and transgene plasmid co-transfected into HEK293T cells to 
produce shRNA containing lentivirus particles. The lentiviruses are 
transduced into target cells and the shRNA integrated into host genome 
after successful transfection. Short hairpin RNA is transcribed and 
processed to produce siRNA which suppresses target mRNA. 
 
1.7 Objectives 
This study is composed of three main objectives in order to understand the 
importance of the role of BTK in acute myeloid leukaemia subtypes.  
1. To determine the BTK and p-BTK distribution in the cytoplasm and 
nucleus and the role for BTK in the nucleus. 
2. To identify whether Gα12 or Gα13 G-protein subclasses transduce 
signalling information from the CXCR4 chemokine receptor. 
3. To determine whether BTK can transduce the chemokine signal 
through Gα12 or Gα13. 
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Materials and Methods 
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2.1 Materials 
2.1.1 Reagents and Materials 
Most of the chemical reagents were purchased from Fisher Scientific or 
otherwise stated if those chemicals were purchased from other 
companies. 
 
2.1.2 Cell lines 
U937, THP-1, HL-60, and OCI-AML3 were obtained from American Type 
Culture Collection (ATCC). U937 and THP-1 are acute monocytic 
leukaemia cells classified as AML M5 according to FAB classification 
system. THP-1 harbour t(9;11) and MLL-AF9 translocation while U937 
carries t(10;11)(p13;q14) translocation (Tsuchiya et al., 1980, Sundstrom 
and Nilsson, 1976). HL-60 is an acute promyelocytic leukaemia line which 
classified into M2/M3 and bears c-myc mutation and several chromosomal 
abnormalities (Birnie, 1988). Kasumi-1 is a t(8;21) translocation caused 
AML1-ETO gene fusion with a c-kit mutation in the tyrosine kinase domain 
and is classified into AML M2 subtype (Asou et al., 1991). OCI-AML3 is 
AML M4 carrying a nucleoplasmin mutation in exon 12 (Quentmeier et al., 
2005). JEKO-1 (Mantle Cell Lymphoma), OCI-LY19 (B cell lymphoma), 
and Kasumi-1, are kindly gifted from Dr. Joseph Slupsky’s laboratory. 
Human embryonic kidney cells (HEK293T) was kindly given from other 
laboratories (John Quinn). 
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Cell lines Leukaemia Subtype  
OCI-AML3 AML M4  
HL-60 AML M2/M3 
U937 AML M5 
THP-1 AML M5 
Kasumi-1 AML M2 
Jeko-1 Mantle Cell Lymphoma 
OCI-LY19 B cell lymphoma 
 
Table 2.1 AML and CLL cell lines.  
This table shows the detail of AML and CLL cell lines that we used as 
models in this study. AML cell lines were classified according to France-
American-British Classification (FAB) where AML was classified into 7 
subclasses from M0-M7 according to their genetic abnormality. 
 
 
2.1.3 Antibodies 
Antibodies were purchased from Cell Signalling Technology. The anti-
mouse and anti-rabbit secondary antibodies conjugated to horseradish 
peroxidase (HRP) were obtained from Santa Cruz Biotechnology. The 
specific company will be stated if antibodies were purchased from other 
sources. Details of each antibody are shown in Tables 2.2 and 2.3. 
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Primary 
Abs 
Type Host Dilution MW 
(kDa) 
Company 
p-BTK (Y223) Polyclonal 
  
Rabbit 1:1000 76 Cell signalling 
technology® 
p-BTK (Y223) 
(D9T6H) 
Monoclonal Rabbit 1:1000 76 Cell signalling 
technology® 
BTK (D3H5) Monoclonal Rabbit 1:1000 76 Cell signalling 
technology® 
p-Erk1/2 Polyclonal Rabbit 1:2000 42 and 
44 
Cell signalling 
technology® 
p44/42 
MAPK 
(Erk1/2) 
Polyclonal Rabbit 1:2000 42 and 
44 
Cell signalling 
technology® 
p-PLCϒ2 Polyclonal Rabbit 1:2000 150 Cell signalling 
technology® 
PLCϒ2 (B-
10) 
Monoclonal Rabbit 1:2000 150 Santa Cruz 
Biotechnology 
Gα12 (S-20) Polyclonal Rabbit 1:500 42 Santa Cruz 
Biotechnology 
Gα13 (A-20) Polyclonal mouse 1:200 42 Santa Cruz 
Biotechnology 
Anti-β-actin Monoclonal Mouse 1:10000 42 Sigma 
GAPDH Monoclonal Rabbit 1:2000 30 Cell signalling 
technology® 
 
Table 2.2 List of primary antibodies. 
Primary antibodies used are described in this table.  
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Secondary 
Abs 
Conjugated 
Substrate 
Host Dilution MW 
(kDa) 
Company 
Anti-rabbit 
IgG 
Horseradish 
peroxidase 
conjugate 
Goat 1:5000 - Santa Cruz 
Biotechnology 
Anti-mouse 
IgG 
Horseradish 
peroxidase 
conjugate 
Goat 1:5000 - Santa Cruz 
Biotechnology 
Anti-rabbit 
IgG 
Horseradish 
peroxidase 
conjugate 
Goat 1:3000 - Cell signalling 
technology® 
Anti-mouse 
IgG 
Horseradish 
peroxidase 
conjugate 
Horse 1:3000 - Cell signalling 
technology® 
 
Table 2.3 List of secondary antibodies. 
Secondary antibodies used are described in this table.  
 
 
2.2 Methods 
2.2.1 Sterile cell culture maintenance 
Cell culture medium and supplements were purchased from Gibco Life 
Technologies. The AML cell lines which were U937, HL-60, MV4-11, OCI-
AML3, and Kasumi-1 were cultured in Rosewell Park Memorial Institute 
(RPMI) 1640 supplemented with 10% foetal bovine serum (FBS) and 1000 
unit/mL of penicillin/streptomycin (Pen/Strep). The OCI-LY19 cell line was 
grown in RPMI 1640 media supplemented with 20% FBS and 1000 
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units/mL of Pen/Strep. The Human Embryonic Kidney 293T (HEK293T) 
cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% FBS and 1000 unit/mL of Pen/Strep. Cells were 
incubated under 37ºC, 5% CO2 environment. Cell sub-culturing was 
performed regularly. 
 
2.2.2 Cryopreservation and cell recovery 
To store cells, they were maintained in culture conditions until they 
reached exponential growth phase. Cells were harvested by centrifugation 
at 200 x g for 5 min, culture medium was removed, the pellet was 
resuspended in freezing medium (10% DMSO (Sigma Aldrich, UK) + 90% 
FBS) and transferred to cryovials (Corning, UK). Cells were placed in a ‘Mr 
Frosty’ freezing container and kept at -80ºC for 24 h to allow temperature 
to be gradually reduced before transferring to liquid nitrogen for long-term 
storage. 
 
To recover cells from liquid nitrogen, cryovials containing cells were rapidly 
thawed in water bath at 37ºC. The complete medium was added directly to 
the cryovial tube then transferred to 15 mL tube 10 volumes of complete 
medium. Then cells were spun at 200 x g for 5 min removing dead cells 
and DMSO because DMSO has cytotoxic effects on the cells. Cell pellets 
were re-suspended in an appropriate volume of complete medium then 
transferred to appropriate cell culture vessel and incubated at 37οC, 5% 
CO2. 
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2.2.3 Molecular Biology Techniques 
2.2.3.1 RNA extraction and complementary DNA synthesis 
RNA extraction was performed following the protocol from Qiagen’s 
RNeasy Mini Kit (Qiagen, UK). Cells at 5 x 105 cells per sample density 
were pelleted at 300 x g for 5 min at 4ºC. Cells were lysed with Buffer RLT 
and vortexed for 1 min. The homogenized sample was stored at -80ºC or 
used for mRNA extraction immediately. Then 1 volume of 70% ethanol 
was added to cell lysate with repeat pipetting until homogenized. Next, this 
was applied onto an mRNA binding column before spinning at 1,200 x g 
for 20 s. The column was washed with 700 µL of RW buffer and spun at 
1,200 x g for 20 s then 500 µL of RPE buffer was added onto the column 
which was spun as above. Another 500µL of RPE buffer was then added 
and spun at the same speed for 2 min. The empty column was spun at 
1,400 x g for 2 min to remove the remaining RPE buffer. Warm 
DNase/RNase free water was added to column to elute RNA then the 
column was left on the bench for 5 min before spinning at 1,200 x g for 1 
min. The elution step was performed twice and RNA concentration was 
measured by NanoDrop Spectrophotometer.  
 
The complementary DNA (cDNA) was synthesized with iScript cDNA 
synthesis kit (BIO-RAD, UK) as per manufacturer’s protocol. The protocol 
comprises three main steps which are priming at 25ºC for 5 min, reverse 
transcription at 46ºC for 20 min, reverse transcriptase inactivation at 95oC 
for 1 min, and an optional step to hold the reaction at 4ºC. 
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2.2.3.2 Protein extraction and quantification 
In order to examine the expression of interested proteins, cells were 
centrifuged at 800 x g, 4ºC for 1 min and supernatant was removed. The 
cell pellet was washed once with 1 x ice-cold PBS and pelleted again at 
800 x g, 4ºC for 1 min. PBS was prepared by dissolving 1 PBS tablet 
(Sigma Aldrich, UK) with 200 mL of MilliQ and sterilising in an autoclave at 
121ºC for 15 min. The harvested cells were lysed with SDS clear sample 
buffer (1% SDS, 50 mM Tris-HCl pH6.8, 5 mM EDTA, and 10% glycerol) 
100 μL per 3 x 106 cells. Then DNA was removed by sonication and 
protein was boiled at 95ºC for 5 min. Cell debris and unbroken cells were 
cleared by spinning at 1,400 x g for 10 min. The supernatant containing 
protein was transferred to pre-chilled Eppendorf tubes and stored at -20ºC 
for further experimentation. 
 
Bovine serum albumin (BSA) (Sigma Aldrich, UK) was used as a protein 
standard for the detergent-compatible assay (DC Assay) by 2-fold serial 
diluting in SDS clear lysis buffer from 2 mg/mL to 0 mg/mL Protein 
quantification is a critical step for investigation of the expression level of 
targeted proteins. The DC assay kit was composed of Reagent A, 
Reagent S, and Reagent B. Five microliters of blank, standards ranging 
from 0.125 mg/mL to 2 mg/mL, and protein samples were added into 
separate wells of a 96-well plate. Then 25 µL of AS solution mixture (50:1 
ratio) was added to each well before 200 µL of Reagent B was added on 
top of the AS mixture. The plate was incubated for 10 min (room 
temperature) before reading absorbance at 750 nm on plate reader. DC 
Assays were performed in duplicate. 
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2.2.3.3 Western Blotting 
Protein was separated by electrophoresis according to molecular weight. 
The sodium dodecyl sulphate-polyacrylamide (SDS-PAGE) was prepared 
by using gel setting apparatus (BIO-RAD, UK). Different percentages of 
polyacrylamide gels were used according to size of the targeted protein. 
The resolving gel and stacking gel were prepared as shown in Table 2.4. 
The resolving gel was poured between glass plates on the casting frame, 
70% ethanol was overlain on top of the gel which was allowed to 
polymerize for 30 min. Then the stacking gel was poured on top of the 
resolving gel after 70% ethanol was removed and rinsed with water before 
a comb was inserted between glass plates and the gel was left to 
polymerize for another 30 min. The required protein concentration was 
mixed with lysis buffer and loading dye (5 x loading dye to give a final 1 x 
concentration of  10% glycerol, 5% β-mercaptoethanol, 3% SDS, and 62.5 
mM Tris, pH 6.8) then loaded onto stacking gel. The SDS-PAGE was 
resolved at constant 30 mA per gel. The SDS-PAGE was performed until 
the loading dye reached the bottom of the gel (around 1 h). The transfer 
sandwich was prepared following the order, cassette, sponge, two pieces 
of filter paper, gel, membrane, two pieces of filter paper, and sponge. The 
sandwich was placed into a tank containing cold transfer buffer (25 mM 
Tris Base and 0.2 M glycine). Protein transferring was performed with 
constant 400 mA for 1 h. After that, the membrane was blocked with 
blocking buffer (5% skimmed milk in TBS-T, (10 x TBS; 10 mM Tris, 150 
mM NaCl, pH 8 with 0.1% Tween-20 added after diluted 10 x TBS to 1 x 
TBS) for 1 h, then the membrane was incubated overnight at 4ºC with 
primary antibody. Next day, the membrane was washed with TBS-T twice 
x 15 seconds, twice x 5 min, and a last wash step of 15 min. Membrane 
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was incubated for a further 1 h with the desired primary antibody at the 
required concentration (typically 1:1000).  Primary antibody was then 
washed 3 times with 1 x TBST (5 min each) before incubation for 1 h with 
the necessary species-matched secondary antibody conjugated with 
horseradish peroxidase (HRP), being diluted (typically 1:10,000) in 
blocking buffer (5% skimmed milk in TBS-T). After secondary antibody 
incubation, the membrane was washed with the same protocol for primary 
antibody. In order to detect the interested protein, the membrane was 
incubated with enhanced chemiluminescence (ECL) (Millipore) which 
contains luminol (the substrate of HRP). The light emitted from the 
oxidation reaction between HRP and luminol was detected by X-ray film or 
the ChemiDoc Imaging System from BIO-RAD. A list of primary antibodies 
and secondary antibodies are shown in Tables 2.2 and 2.3. 
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Reagent 8%Resolving gel 10%Resolving gel 
Acrylamide (Geneflow) 4mL 5.7mL 
Resolving Buffer 4.25mL 4.25mL 
MilliQ  8mL 7.05mL 
APS (Thermo Scientific) 50μL 50μL 
TEMED (Sigma-Aldrich) 15μL 15μL 
 
Reagent 5%Stacking gel 
Acrylamide (Geneflow) 4.36mL 
Stacking Buffer 1.9mL 
MilliQ  1.24mL 
APS (Thermo Scientific) 50μL 
TEMED (Sigma-Aldrich) 15μL 
 
Table 2.4 Sodium dodecyl sulphate polyacrylamide gel (SDS-PAGE) 
electrophoresis. 
Protein was separated according to molecular weight on different 
percentages of acrylamide. 
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2.2.4 Cell Fractionation 
This protocol was adapted from Trentin L et al, blood, 2008 (Trentin et al., 
2008) . In order to examine the phosphorylation pattern and expression of 
BTK in different cellular compartments, 5 x 107 cells were harvested, 
centrifuged for 5 min at 200 x g and washed once with ice-cold PBS. The 
pellet was lysed with isotonic buffer (50 mM Tris-HCl pH 7.5, 0.25 M 
saccharose), transferred to pre-chilled 1.5 mL Eppendorf tubes and 
subjected to 3 times sonication on ice with 25% amplitude for 5 seconds, 
with 15 second intervals between each 5 second burst. After sonication, 
the lysate was pelleted at 10,000 x g for 10 min with nuclear protein 
present in this pellet. The supernatant which contains cytoplasmic protein, 
light membrane protein, and heavy membrane protein, was transferred to 
a new pre-chilled 1.5 mL Eppendorf tube and were separated further as 
described below.  
 
To isolate nuclear protein, the pellet from above sample was washed once 
with ice-cold PBS and spun at 10,000 x g for 10 min to remove 
contaminants before being lysed with clear SDS-PAGE sample buffer (1% 
SDS, 50 mM Tris-HCl pH 6.8, 5 mM EDTA, and 10% glycerol). The 
nuclear lysate was further sonicated at 40% amplitude for 10 seconds. 
This fraction was analysed later as a nuclear protein fraction. 
 
In order to separate other cellular fractions, the previous supernatant from 
the first step, was spun at 16,000 x g for 30 min. The supernatant was 
transferred to a new pre-chilled tube which contained light membrane and 
cytoplasmic protein mixture. At the same time, the pellet was washed once 
with ice-cold PBS and centrifuged again at the same speed and time. 
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Then protein was sonicated with 40% amplitude for 10 sec. This fraction 
was referred as a heavy membrane protein fraction.  
 
The last fraction which is the mixture of light membrane protein and 
cytoplasmic protein was ultra-centrifuged at 105,000 x g for 1 hour. Then  
the supernatant was transferred to a new pre-chilled 1.5 mL tube. This 
fraction was analysed as cytoplasmic protein fraction. The pellet from 
this fraction was washed once with ice-cold 1 x PBS and lysed with clear 
SDS-PAGE sample buffer. This fraction was sonicated with 40% amplitude 
for 10 sec in order to get light membrane protein fraction.  
 
2.2.5 CXCR4 staining on AML and CLL cell lines  
AML and CLL cell lines were cultured in serum-free RPMI overnight at 5 x 
105 cells density in 24-well plate. On the day of the experiment, cells were 
pelleted at 500 x g for 5 min then resuspended in 100 μL of PBS. In order 
to stain surface CXCR4 receptor, cells were incubated with 25 μg/mL of 
CD184-PE antibody or 25 μg/mL of mouse IgG2a-PE for CXCR4 receptor 
and isotype control, respectively. Cells were incubated in darkness for 20 
min before washing once with 1 x PBS at 2000 x g for 2 min. Then pellets 
were resuspended with PBS and the stained cells were analysed for the 
expression of the CXCR4 receptor by FACS analysis. 
  
60 
 
2.2.6 SDF-1α treatment in AML and CLL cell lines  
AML and CLL cell lines were seeded on 6-well plates at 1 x 106 – 3 x 106 
cell/mL in serum-free RPMI overnight. Cells were treated with 100 ng/mL 
of SDF-1α in time-course from 0, 1, 5, 10, 20, and 30 min and incubated at 
37ºC. Cells were pelleted at 500 x g for 1 min at 4ºC and whole cell protein 
extraction performed as described in section 2.2.3.2 and SDS-PAGE and 
Western blot according to the section 2.2.3.3. Phosphorylated BTK (Y223) 
and BTK were probed for in order to investigate down-steam signalling 
molecules of the SDF-1α/CXCR4 signalling pathway. 
 
2.2.7 Gα12/Gα13 knockdown by lentivirus technology and functional 
assay 
2.2.7.1 Bacteria Transformation 
Escherichia coli strain C3040 was used as a bacterial host for plasmid 
transformation. Bacteria and plasmids were mixed and incubated on ice 
for 30 min. The heat shock transformation was performed by incubating 
bacteria-plasmid mixture at 42ºC for 1 min with the mixture replaced 
directly on ice for 2 min afterward. The 350 μL of super optimum broth with 
catalytic suppression medium (SOC) (SOB with 1 mL of 2 M glucose) was 
added and bacteria culture was agitated at 37ºC for 1 h to recovery. 100 
µL of transformed bacteria were plated on LB agar containing selective 
antibiotic according to plasmid backbone and the rest of the bacterial 
culture was spun at 500 x g for 5 min and approximately 200 µL of the 
supernatant was removed and the bacterial pellet was resuspended with 
the remained culture and plated on another LB agar plate. Bacteria were 
grown at 37ºC for 16 h. Short hairpin RNA plasmids were obtained from 
the RNAi consortium shRNA library (Broad Institute, MIT) by Dr. Mark 
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Glenn. The short hairpin RNA plasmids pLKO.1 vector contained shRNA 
sequences for Gα12 or Gα13 and puromycin resistance gene as a 
selectable marker with gene expression driven by human U6 promoter. 
 
2.2.7.2 HEK293T transfection by using JetPEI 
In order to investigate the knockdown ability of each shRNA plasmid, 
HEK293T was used as a screening system to select the efficient shRNA 
plasmid able to knockdown the gene of interest in hematopoietic cells 
transfection. At day one, HEK293T cells were seeded at 2 x 105 cells per 
well on 6-well plates and cultured until cells reached confluence. Five 
hundred of each shRNA plasmid were mixed with 150 mM NaCl in a final 
volume of 100 μL. Four microliters of JetPei were mixed with 96 μL of 150 
mM NaCl, then JetPei mixture was added into DNA mixture, vigorously 
vortexed and incubated at room temperature for 20 min before dropwise 
addition onto seeded HEK293T cells. The transfected cells were incubated 
in cell culture conditions for 3 days before knockdown efficiency was 
examined by Western blotting. 
 
2.2.7.3 Lentivirus production 
The third generation lentivirus plasmid was used in this thesis in which the 
necessary genes for viral production were separated into three different 
plasmids. HEK293T cells were plated at 3 x 105 cells/ mL of 10% FCS 
DMEM without antibiotics in 10 cm petri-dish for 18 to 20 h. On the next 
day, the transfer plasmid which is pLKO.1 containing Gα12- or Gα13-
targeted shRNA and the three lentivirus plasmids (pCMV-VSV-G, pRSV 
REV, and pMDLg/pRRE) were mixed in ratio 4:2:2:2 by using JetPei as a 
carrier to deliver plasmid into host cells. Culture medium was changed 
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after 24 h post transfection (h.p.t.) and further incubated for 3 days. The 
virus particles produced were collected from supernatant at 48 h and 72 h 
post transfection (h.p.t.). The viral particles were concentrated by 
ultracentrifugation at 25,000 x g, 4ºC for 2 h then the supernatant was 
removed and tubes were put upside down in order to dry the remaining 
liquid. The viral particles were resuspended with sterile PBS in 1:1000 
dilution and left at 4ºC for complete resuspension. Finally, viruses were 
aliquoted and stored at -80ºC until needed for experimentation. 
 
2.2.7.4 Lentivirus transduction in AML and CLL cells  
OCI-AML3 and OCI-LY19 cells were seeded at 4 x 105 cell/mL (0.5 mL 
volume/well) in 24-well plates with complete medium in the presence of 8 
μg/mL polybrene on the day of the experiment. Then shRNA containing 
viruses were transfected into the cells by spinoculum method, in which 16 
µL of the virus was added onto cells and the plate spun at 120 x g, 37ºC 
for 1 h. 0.5 mL of medium was added to the transduced cells after 4 h to 
dilute polybrene final concentration to 4 g/mL and transduced cells were 
incubated for 24 h. On the next day, transduced cells were pelleted at 150 
x g for 5 min and the supernatant was replaced by new complete medium. 
Cells were incubated for further 3 days before the transduced cells were 
selected using 2-4 μg/mL puromycin. 
 
2.2.7.5 Puromycin selection 
The transduced cells were pelleted at 100 x g for 5 min then cultured with 
complete media containing 2-4 μg/mL puromycin in order to select the 
Gα12-, Gα13-targeted shRNA, or scramble control integrated cell 
population. The puromycin containing medium was replaced every 2 days 
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and the puromycin selection was performed for 6 days. The surviving cells 
were harvested and transduction efficiency was checked by Western 
blotting with Gα12 or Gα13 antibody as previously described in section 
2.2.3.3. Transduced cells were reselected with puromycin and 
transduction efficiency checked by Western blotting regularly. OCI-AML3 
wild-type (WT) and OCI-LY19 wild-type (WT) were treated with puromycin 
for control. 
 
 
Short hairpin RNA Gα12 
Clone ID Hairpin sequence Vector Selectable 
marker 
TRCN000003
6757 (E6) 
5'-CCGG-
CGTCAACAACAAGCTCTTCT
T-CTCGAG-
AAGAAGAGCTTGTTGTTGAC
G-TTTTTG-3' 
pLKO.1 Puromycin 
resistance 
TRCN000003
6754 (E7) 
5'-CCGG-
CGAGTGATGATGTTGTGAAT
A-CTCGAG-
TATTCACAACATCATCACTCG
-TTTTTG-3' 
pLKO.1 Puromycin 
resistance 
TRCN000003
6755 (G10) 
5’-CCGG-
GCTGAATTACTTTCCTAGTAA
-CTCGAG-
TTACTAGGAAAGTAATTCAGC
-TTTTTG-3’ 
pLKO.1 Puromycin 
resistance 
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TRCN000003
6756 (G11) 
5'-CCGG-
GCACGAGATAAGCTTGGCAT
T-CTCGAG-
AATGCCAAGCTTATCTCGTGC
-TTTTTG-3' 
pLKO.1 Puromycin 
resistance 
TRCN000003
6758 (H1) 
5'-CCGG-
CCATGCTGTGAAAGACACCA
T-CTCGAG-
ATGGTGTCTTTCACAGCATG
G-TTTTTG-3' 
pLKO.1 Puromycin 
resistance 
Short Hairpin RNA Gα13 
Clone ID Hairpin sequence Vector Selectable 
marker 
TRCN000003
6884 (C7)  
5'-CCGG-
CCGTGACGTGAAGGATACTA
T-CTCGAG-
ATAGTATCCTTCACGTCACGG
-TTTTTG-3' 
pLKO.1 Puromycin 
resistance 
TRCN000003
6885 (C8) 
5'-CCGG-
GCTCGAGAGAAGCTTCATAT
T-CTCGAG-
AATATGAAGCTTCTCTCGAGC
-TTTTTG-3' 
pLKO.1 Puromycin 
resistance 
TRCN000003
6886 (C9) 
5'-CCGG-
GTCTCCATAATTCTGTTCTTA
-CTCGAG-
TAAGAACAGAATTATGGAGAC
pLKO.1 Puromycin 
resistance 
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-TTTTTG-3' 
TRCN000003
6887 (C10) 
5'-CCGG-
GATAAGATGATGTCGTTTGA
T-CTCGAG-
ATCAAACGACATCATCTTATC-
TTTTTG-3' 
pLKO.1 Puromycin 
resistance 
TRCN000003
6888 (C11) 
5'-CCGG-
CAATCGTCAATAACCGGGTT
T-CTCGAG-
AAACCCGGTTATTGACGATTG
-TTTTTG-3' 
pLKO.1 Puromycin 
resistance 
 
Table 2.5 List of short hairpin RNA plasmids. 
This table shows the detail of each shRNA clone used in this study. The 
siRNA specific sequenced is emphasized in bold letter within the hairpin 
sequence. This table was adapted from siRNA library consortium, Broad 
Institute. 
 
2.2.7.6 Chemotaxis transwell migration assay 
In order to investigate the effect of Gα12/Gα13 knockdown upon migration 
in response to SDF-1α/CXCL12, the 8 µm pore size transwell insert was 
used in this experiment. 2 x 105 cells of OCI-AML3 wild-type (WT) and 
Gα12/Gα13 knockdown cells were pelleted and washed once with RPMI 
supplemented with 1% FBS. These cells were resuspended in 100 µL of 
the same medium then plated onto a transwell insert. 200 ng/mL SDF-1α 
was also prepared in 1%FBS RPMI. Then 600 µL of 1% FBS RPMI, 200 
ng/mL SDF-1α, or 10% FBS RPMI were added to the bottom chamber. 
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The transwell plate was incubated at cell culture conditions for 4 h to allow 
cells to migrate toward SDF-1α. Then the migrated cells were harvested 
from lower chamber and counted using trypan blue exclusion staining in 
which cells were counted in triplicate and results were analysed by 
GraphPad Prism6 program. Results were reported as a fold-change 
compared with the untreated control. 
 
2.2.7.7 The effect on survival of Gα protein subunit knockdown cells 
after ibrutinib treatment 
The wild-type (WT), Gα12 or Gα13 knockdown, and scramble control OCI-
AML3 and OCI-LY19 cells were seeded at 1 x 106 cell/ mL in 12-well 
plates. AML and CLL cells were treated with different conditions of 
ibrutinib ranging from 0, 0.1, 0.5, 1, 5, and 10 µM. The control and treated 
cells were incubated for 3 days and cells were treated with 2.5% DMSO 
for 24h as a positive control. The annexin-V/PI was used to stain ibrutinib 
treated cells in order to assess the effect of ibrutinib treatment on cell 
survival. Ibrutinib treated and DMSO treated cells were harvested at 150 x 
g for 5 min and washed once with 1 x binding buffer. Pellets were 
resuspended with diluted annexin-V (1:1000 with 1 x binding buffer) and 
cells were incubated in darkness for 20 min and unbound annexin-V was 
removed by washing cells with 1 x binding buffer once before 
resuspended with 1 x binding buffer. PI was added to the tube before 
annexin-V/PI measurement by FACS analysis.  
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2.2.7.8 Effect of migration on Gα12/Gα13 knockdown cells after 
Ibrutinib treatment 
OCI-AML3 wild-type (WT), Gα12 or Gα13 knockdown, and scramble control 
cells were seeded at 5 x 106 cell/mL in RPMI supplemented with 10% FBS 
and Pen/Strep in 24-well plates. Cells were treated with different 
concentrations of ibrutinib for 2 h. After ibrutinib treatment, cells were 
washed twice with RPMI containing 1% FBS and resuspended with 100 µL 
of 1% FBS RPMI and seeded on transwell insert. Then 600 µL of 1% FBS 
RPMI, 200 ng/mL SDF-1α, or 10% FBS RPMI were added to the bottom 
chamber. Cells were allowed to migrate for 4 h and the migrated cells 
were counted by using trypan blue exclusion staining. The migration assay 
illustration is shown in Figure 2.1. 
 
 
 Figure 2.1 Migration Assay. 
This illustration shows migration assay experiment. Migration assay was 
performed on 8 independent repeats and Student’s T-test was used as a 
statistical test which P-value < 0.05 is considered as a significant 
difference.   
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2.2.7.9 Effect on cytokine production on Gα12/Gα13 knockdown cells 
after ibrutinib treatment 
OCI-AML3 wild-type (WT) and Gα12 subclass knockdown (KD) cells were 
seeded at 2.5 x 105 cell/0.5 mL on 24-well plate. Cells were treated with 
ibrutinib for 2 h then treated continuously with 200 ng/mL SDF-1α for 4 h. 
Tumour necrosis factor-α (TNF-α) was used as a positive control at 20 
ng/mL concentration. After treatment, cells were harvested and subjected 
to RNA extraction followed by cDNA synthesis as described in section 
2.2.3.1. The cytokines expression was analysed by qPCR using the 
SybrGreen detection system. The qPCR primers were designed and 
purchased from Integrated DNA Technologies which shown in Table 2.6 
below. The SybrGreen qPCR reaction was prepared according to table 
2.7. Besides cDNA, each component was prepared in master mix then 
added to the cDNA contained 96-well plate. The 96-well plate was spun 
briefly and loaded into qPCR machine.  
 
The qPCR reaction was performed with 50 amplification cycle. Gene 
expression was calculated from ΔΔCt and fold change of gene expression 
after treatment was compared to untreated condition. GAPDH was used 
as a housekeeping gene expression control which GAPDH primer was 
purchased from Qiagen.    
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Table 2.6 Primer list for qPCR.  
This table shows list of primers used for qPCR. GAPDH was used as a 
housekeeping gene control.  
Gene Forward Reverse Product 
size 
(bp) 
Tm 
IFNA1  CCTCGCCCTTTGCT
TTACT 
GCATCAAGGTCCTC
CTGTTATC 
114 58 
IL-10 TTTCCCTGACCTCC
CTCTAA 
CGAGACACTGGAA
GGTGAATTA 
123 58 
IL-12A CCCGGGAGTTAATC
CGAAAG 
TCTCCTTCTGTGTC
TCTCTCTAC 
95 58 
IL-4 GTTCTACAGCCACC
ATGAGAA 
CCGTTTCAGGAATC
GGATCA 
94 58 
IL-6 GGAGACTTGCCTGG
TGAAA 
CTGGCTTGTTCCTC
ACTACTC 
99 58 
IL-8 CTTGGCAGCCTTCC
TGATTT 
 GGGTGGAAAGGTT
TGGAGTATG 
111 58 
TNFA CAGGTTCTCTTCCT
CTCACATAC 
GTCCCGGATCATGC
TTTCA 
90 58 
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Component Volume (μL) 
2XSybrGreen 5 
Forward and Reverse Primers Mixture 0.5 
RNase free H2O 2 
cDNA (up to 1μg) 2.5 
Total Volume 10 
 
Table 2.7 The SybrGreen qPCR reaction component. 
This table shows the component of qPCR reaction. Apart from cDNA 
template, the other components were prepared as master mix.   
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Chapter III 
 
 
BTK Expression and its 
Subcellular Distribution 
  
72 
 
3.1 Introduction  
Bruton's tyrosine kinase (BTK) is a protein kinase which is predominantly 
expressed in the cytoplasm of cells, however, several reports have 
supported the concept of functional BTK travelling to the nucleus of cells 
as well as its association with the plasma membrane. BTK is crucial for B 
cell development and impairment of normal BTK function in those cells 
can cause defects in B cell development, as well as such defective BTK 
function being linked to the generation and propagation of several types of 
blood cancers. 
 
Upon specific ligand stimulation (for example, B cell receptor linkage to 
antibodies or chemokine ligand interaction with its receptors), BTK can 
translocate to different subcellular compartments within the target cells 
(Hendriks et al., 2014). A GFP-tagged BTK variant was shown to 
associate with the plasma membrane upon PI3K activation, via the 
stimulation of several cell surface receptors, including G-protein-coupled 
receptors, growth factor receptors, and the B cell receptor (Varnai et al., 
2005). In addition, translocation of BTK to the plasma membrane can be 
dependent upon the stimulation of Src protein kinase, with the amount of 
BTK at the plasma membrane increasing in relation to the levels of Src 
and BTK-GFP co-transfection (Nore et al., 2000). Another study from this 
group also showed the domains of BTK that appear important for the 
process of translocation to the plasma membrane and proposed a 
shuttling mechanism between cytoplasm and nucleus, using leukaemic 
and non-leukaemic cells as model systems. Their results showed BTK 
translocates to the nucleus in both exogenously transfected cells systems 
and endogenously BTK-expressing cells. Moreover, the PH and SH3 
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domains of BTK were reported to be involved in the BTK translocation 
process. BTK which harbours mutations within its pleckstrin homology 
(PH) domain were redistributed in a manner showing equal distribution in 
both cytoplasm and nucleus regions within cells.  BTK was also found to 
be predominantly found in nuclear compartments when SH3 domain 
mutations were present (Mohamed et al., 2000).  Thus, subcellular 
distribution of BTK between cytoplasmic, membrane and nuclear areas is 
achievable in cells and involves its PH and SH3 domains. 
 
BTK distributes to several cellular compartments upon its activation 
including the nucleus, although its role at the nucleus is speculative at 
present. Clearly, BTK can readily shuttle to the nucleus, hence, this 
information implies that BTK may have significant functional role in each of 
these cellular compartments. Here, we focus on BTK translocation to 
nucleus, as most of studies were performed in non-leukaemic cells and 
normal B cells. Moreover, the role of BTK in the nucleus of leukaemia 
cells, especially AML and CLL subtypes, is still elusive. Therefore, this 
experimental chapter aims to investigate the distribution of BTK in the 
cytoplasm and nucleus on AML and CLL cell lines, to enlighten our 
understanding of any role for BTK in the nucleus in human leukaemic 
cells. 
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3.2 Results 
As this chapter aims to investigate BTK expression in different subcellular 
compartments, protein extraction protocols and p-BTK antibody Western 
analyses were optimised.  Due to the poor nature of the p-BTK antibodies 
commercially available, extensive optimisation was performed.  The data 
presented within this chapter represents the optimal protocols that were 
exhaustively undertaken. 
 
3.2.1 Protein extraction optimisation 
In order to extract cytoplasmic protein and nuclear protein from human 
leukaemic cells, two protein extraction protocols were performed. The first 
protein extraction protocol was not described fully in the Method section, 
thus the protocol is briefly described here. Cells were harvested at 5 x 106 
cells density collected by centrifugation at 1,000 x g for 5 min, then the cell 
pellet was washed once with 1 x ice-cold PBS (4ºC). The cell pellet was 
lysed with isotonic lysis buffer. In these experiments, the cell pellet was 
sonicated for 5 min in a sonic bath, then placed on ice for 1 min – this 
sonication cycle was repeated three times (15 min bath sonication in total).  
The lysate was then spun at 1,000 x g for 10 min (4ºC). The supernatant 
was regarded as the cytoplasmic protein. The remaining pellet was 
washed once with 1 x ice-cold PBS. In order to extract nuclear protein, 
clear SDS sample buffer was used to lyse the cell pellet, before sonication 
for a further 5 min (repeated three times) using the sonic bath method. 
Cell debris was removed by centrifugation at 1,200 x g for 20 min then the 
supernatant was collected and analysed as nuclear protein.   
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The results showed protein contamination of cytoplasmic and nuclear 
protein when the sonic bath method was used, as shown in Figure 3.1. 
Phosphorylated BTK could not be detected in the Western blot (see Figure 
3.1) which we considered as an antibody quality issue. Focusing on the 
cytoplasmic markers β-actin and GAPDH, these two cytoplasmic proteins 
were detected in both cytoplasm and nucleus fractions, whereas 
conventionally, they are believed to be found only in cytoplasm fractions of 
cells. Therefore, we concluded that this protocol was not sufficient to give 
good protein extraction and cell fractionation for sub-cellular studies.  
 
The second method tested was sonic probe-fractionation of protein from 
leukaemic cell lines, as described in the Materials and Methods section. 
As shown in Figure 3.2, only trace amounts of β-actin were found in the 
nuclear fraction while GAPDH was detected only in cytoplasmic protein 
fraction. Therefore, this protocol was more suitable for cell fractionation 
studies, and was used for the more detailed experiments in this chapter.  
 
3.2.2 Phosphorylated BTK antibody optimisation 
As mentioned above, the p-BTK (Y223) antibody was difficult to gain a 
consistent band for analysis.  Thus, we endeavoured to test different 
protein and antibody concentrations to optimise our consistent detection of 
the phosphorylated form of BTK in cytoplasmic and nuclear fractions. First, 
p-BTK (Y223) cannot be detected when 2.5 g of fraction protein was 
loaded and probed with the p-BTK at a dilution of 1:300. Therefore the 
protein level was increased to 20 g, with the antibody dilution at 1:300.  
The result showed that p-BTK was slightly detected in both cytoplasmic 
protein and nuclear protein. The last condition in Figure 3.2C was the best 
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condition for this antibody to consistently detect p-BTK, where 20 g 
protein was subjected to SDS-PAGE and antibody concentration 
increased to 1:150 to probe for BTK protein phosphorylation by Western 
blot. This extraction protocol and concentration of protein and antibody 
dilution was applied in all subsequent experiments. 
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Figure 3.1 Cytoplasmic and Nuclear protein content in human 
leukaemia cell lines extracted by the sonic bath method. 
Human leukaemic cell lines had cytoplasmic and nuclear extracts 
prepared as described in the text of this chapter. Western blotting analysis 
of the indicated proteins was performed. The arrows indicate the expected 
molecular mass of each of the proteins (BTK, 77 kDa; β-actin 45 kDa; 
GAPDH, 37 kDa).  
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Figure 3.2 Cytoplasmic and Nuclear protein content in human 
leukaemia cell lines extracted by sonic probe. 
Human leukaemic cell lines had cytoplasmic and nuclear extracts 
prepared as described in the Materials and Methods section. The sonic 
probe method was used in this protocol. Western blotting analysis of the 
indicated proteins was performed. The arrows indicate the expected 
molecular mass of each of the proteins (BTK, 77 kDa; β-actin 45 kDa; 
GAPDH, 37 kDa). 
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Figure 3.3 Phosphorylated BTK expression in cytoplasm and nucleus 
on AML and CLL cell lines (antibody optimisation). 
Human leukaemic cell lines had cytoplasmic and nuclear extracts 
prepared as described in the Materials and Methods chapter. Western 
blotting analysis of the indicated proteins was performed, with arrows 
indicating the expected molecular mass. Different antibody and protein 
concentration were optimised which are 2.5 μg protein and 1:300 antibody 
dilution (A), 20 μg protein and 1:300 antibody dilution (B) and 1:150 
antibody dilution (C), respectively.  
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3.2.3 Phosphorylation pattern of BTK (Y223) in the subcellular 
compartments of leukaemic cell lines 
As we aimed to investigate the phosphorylation of BTK in the two sub-
cellular compartments (cytoplasm and nucleus) in AML and CLL lines, we 
performed optimal fractionation and p-BTK (Y223) expression was analysed 
by Western blotting. JEKO-1 and OCI-LY19 were used as CLL model cell 
lines, while U937, HL-60, and THP-1 are AML cell lines. As shown, 
endogenous BTK levels were substantially different among the cell lines 
tested as each lane showed different band intensity, compared to GAPDH 
intensity which was relatively equal among each sample. Phosphorylated 
BTK was found in both nuclear and cytoplasmic fractions from U937, THP-
1, HL-60, JEKO-1, and OCI-AML3. The phosphorylated BTK expression 
correlated well with the total BTK found in each cell line – thus, cells that 
expressed BTK also expressed phospho-BTK, whether it be found in their 
cytoplasmic or nuclear compartments. GAPDH as a cytoplasmic marker, 
was detected only in the cytoplasmic fractions from each cell line.  
Therefore, we are confident that nuclear BTK or p-BTK was not merely 
cytoplasmic protein contamination. As another test of the purity of the 
fractions, we tested the samples for histone H-3, which is believed to be a 
purely nuclear-located protein. While the majority of H3 signal was found 
in the nucleus, some minor protein was detected in the cytoplasmic 
fractions of these cells.  However, in general there was clear distinction 
between the cytoplasmic and nuclear fractions, and we definitively showed 
there to be BTK (and p-BTK) present in both sub-cellular fractions.  
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Figure 3.4 Phospho-BTK (Y223) phosphorylation pattern in cytoplasm 
and nuclear area of human leukaemia cell lines. 
U937, THP-1, and HL-60 AML cell lines and JEKO-1 and OCI-LY19 CLL 
cell lines were fractionated and analysed as described previously. The p-
BTK and total BTK expression were investigated in the cytoplasmic and 
nuclear fractions. The GAPDH and Histone H3 proteins were compared as 
markers for cytoplasmic and nuclear proteins, respectively. The arrows 
indicate the expected molecular mass of each of the proteins (BTK, 77 
kDa; β-actin 45 kDa; GAPDH, 37 kDa; Histone H3, 17 kDa). 
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3.3 Discussion 
This chapter aimed to investigate the expression of BTK in the nucleus 
and cytoplasm of human leukaemic cell lines, and to determine the optimal 
protocol for efficiently measuring cytoplasmic and nuclear protein 
extraction and p-BTK antibody usage, to obtain a reliable and consistent 
result. 
 
The result showed different protein extraction efficiency between the two 
protocols used. The first protocol, using a sonic bath, where the pellet was 
not washed properly after cytoplasmic protein collection. There was 
obvious contamination of protein between the two fractions as detected by 
β-actin, with the contamination being even more pronounced when 
measuring GAPDH levels. The second protocol, using a higher energy 
sonic probe to disrupt cells, and the extracts washed more fully to remove 
the remaining protein from the two fractions, showed less contamination 
and more precise results when protein expression was compared between 
the two sub-cellular compartment fractions. Therefore, the second protocol 
was applied for the remainder of the experiments.  
 
Earlier work from the lab showed that BTK was expressed in AML cell line 
and AML patient samples (Rushworth et al., 2014). At the time, there was 
considerable skepticism about the presence of BTK in any myeloid cells, 
as BTK was seen to be associated with B cell receptor activation 
mechanisms only. This earlier study also suggested by 
immunohistochemistry, that BTK was indeed present in AML cells and that 
some of the BTK may be expressed in or near the nucleus of the cell.  
Here we have definitively shown for the first time, that BTK is indeed 
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present in AML cells, and that its total level are comparable to the levels 
seen in lymphoid cells, such as CLL.  Moreover, we have shown 
conclusively for the first time, that BTK is present in both the expected 
cytoplasmic regions of AML and CLL cells, but also more surprisingly in 
the nuclear compartments of all these cells too. 
 
Although, p-BTK (Y223) was not detected initially in our studies, our studies 
did reveal that BTK was expressed in AML cells.  BTK is accepted as an 
important signalling protein in B cells. Therefore, we hypothesised that our 
p-BTK (Y223) antibody and protein loading were not used at a suitable 
concentration, and we persevered with antibody optimisation throughout 
this chapter, ultimately proving that our hypothesis is correct and that p-
BTK is present in both AML and CLL cells.  
 
After protein extraction protocol and adequate amounts of both antibody 
and protein loading were stablished, we turned our consideration to the 
main objective of this study in which we aimed to investigate the 
expression of BTK in cytoplasm and nucleus of AML and CLL cells. Our 
results show p-BTK (Y223) and its total counterpart is presented in both 
cytoplasm and nucleus. According to the protein marker for each fraction, 
it is obvious that the nuclear fraction was relatively pure for cytoplasmic 
proteins. Therefore, that both p-BTK and BTK being found in nucleus was 
reliable, even if there were any cytoplasmic protein contamination at low 
levels. Nevertheless, we cannot definitively compare and quantitate the 
absolute expression levels of these proteins in both fractions, since a 
small amount of Histone H3 nuclear protein was found in the cytoplasmic 
fraction. Nonetheless, we have proven for the first time, that BTK is 
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present in the nucleus of AML and CLL cells, notwithstanding any possible 
contamination issues of cytoplasmic protein found in our nuclear extracts. 
 
Several studies showed evidence of BTK in the nucleus of other cells.  In 
terms of how BTK may translocate to the nucleus and any putative role of 
BTK at the nucleus, there remains much conjecture. A small amount of 
phospho-BTK was found in the nucleus of transfected COS7 cells and B 
cells, even though this protein mainly expresses in the cytoplasm. The 
investigation revealed that BTK travels to the nucleus, and interestingly, 
that BTK may need other proteins to help in shuttling between the two 
cellular compartments.  A nuclear localisation signal (NLS) was found in 
the PH domain of BTK in these studies (Mohamed et al., 2000). BAM11 
and ANKRD53 (the latter also known as Liar) co-localised with BTK in the 
nucleus. Both BTK and BAM11 were found in the nucleus and truncated 
BAM11, amino acid 240-368, inhibited BTK kinase activity and reduced IL-
5 stimulation in transfected cells (Kikuchi et al., 2000). Liar or ANKRD53 is 
an SH3 domain-binding protein with a NLS and nuclear exported signal 
(NES) embedded within its sequence. Liar interacts with BTK inside the 
nucleus, which can shuttle and accompany BTK to the cytoplasm as a 
complex (Gustafsson et al., 2012).  
 
Since a small amount of BTK is able to shift to nucleus, this protein may 
perform some crucial functions inside this organelle. Considering the 
phosphorylation state of BTK in the nuclear fraction, this protein may have 
an important role in the nucleus, whereby it probably regulates other 
proteins via a partner or directly controls functions by itself. BTK binding 
partner proteins were revealed by several research groups. BTK 
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Associated Molecule-11 (BAM11), one of the proposed partner proteins of 
BTK, was identified by co-immunoprecipitation studies. The interaction of 
BTK and BAM is a paradoxical relationship because BAM-11 acts as 
negative regulator of BTK, as BTK kinase activity was found to be 
decreased in the presence of truncated BAM-11 (amino acid 240-368) 
while BTK also enhances BAM transcriptional co-activation activity when 
these two proteins were co-transfected. In addition, TFII-I also enhances 
the BTK-dependent transcriptional co-activation activity of BAM (Hirano et 
al., 2004, Kikuchi et al., 2000), with the study showing BAM-11 and BTK 
co-localisation at the nucleus. The putative role of BTK in the nucleus has 
been reported where NF-κB and TFII-I were identified as a target for BTK 
regulation. The TFII-I was identified as a BTK target which required BTK 
for its phosphorylation and transcriptional activity in COS7 cells and 
mouse B cells (Novina et al., 1999). Interestingly, B cell regulator of Ig 
heavy chain transcription called Bright, is a transcription factor that 
enhances transcription of the Ig gene in B cells, was reported as a direct 
target of BTK in the nucleus in both B cells and COS7 cells. In the 
absence of BTK, Bright cannot form DNA binding complexes, therefore 
Bright requires BTK in order to perform its nuclear functions (Rajaiya et al., 
2005). 
 
In summary, p-BTK and BTK were detected in both cytoplasm and 
nucleus in all AML and CLL cell line models tested. In further work, we 
attempt to investigate the mechanism of BTK translocation in AML and 
CLL leukaemia subtypes, as the nuclear shuttling to and the role of BTK at 
the nucleus, are not well understood. BTK wild-type and different mutated 
domains BTK could be transfected into AML and CLL to help identify the 
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different protein binding partner between wild-type and mutant BTKs. The 
co-localisation of BTK wild-type and mutants together with candidate 
protein would help us to understand the mechanism of BTK function at the 
nucleus. Since leukaemia is a heterogeneous disease and the disease 
mechanisms may vary considerably among patients, we also aim to 
investigate the role of BTK in the nucleus from patient samples to better 
fulfil our understanding of BTK in leukaemia.  
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Chapter IV 
 
 
Bruton’s Tyrosine Kinase is 
downstream of the SDF-1α/CXCR4 
signalling pathway in AML and 
CLL 
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4.1 Introduction  
The SDF-1α/CXCR4 signalling pathway plays several important cellular 
roles in both normal and malignant cells.  These cellular responses include 
migration, tissue homing of blood cells, survival and differentiation and 
development (Nagasawa, 2014). This pathway is well characterized in 
normal and cancer cells. CXCL12, also known as stromal derived factor-1 
alpha (SDF-1α), is a chemokine secreted from stromal cells in bone 
marrow (Nagasawa et al., 1996). SDF-1α attracts CXCR4 expressing cells 
which then migrate toward SDF-1α secreted microenvironmental niches 
and attach beside bone marrow stromal cells to provide them with pro-
survival signals. In cancer, this pathway also influences cell migration, 
survival, and in addition, protects cancer cells from drug-induced 
apoptosis (Burger and Kipps, 2006). 
 
Despite BTK being critical and participating in many vital signalling 
pathways in normal B cells or B cell malignancies, this protein is mostly 
regarded as being involved in lymphocytes with pathways including B cell 
receptor signalling and SDF-1α/CXCR4 signalling pathways. Here we 
focus on SDF-1α/CXCR4 axis, BTK has been reported as a part of this 
pathway when signalling molecules upstream and downstream of BTK and 
BTK itself are activated upon SDF-1α ligand binding to CXCR4 receptor 
(Chen et al., 2016). There are several studies that provide evidence to 
support SDF-1α/CXCR4 being a BTK-dependent signalling pathway in 
normal B cells and B cell malignancies.  Mostly these are based upon the 
pharmacological inhibition of BTK using ibrutinib and the examination of 
the resulting downstream inhibitory effect on the cells investigated. BTK 
inhibition causes lymphocytes to egress from the lymphoid tissue, in vivo – 
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a process known as lymphocytosis (Chen et al., 2016). There is evidence 
showing that BTK may be important in AML, and indeed ibrutinib has been 
considered as a potential therapeutic drug in this leukaemia subtype 
(clinicaltrials.gov). Studies from our lab have shown ibrutinib increases 
cytarabine and daunorubicin chemotherapeutic sensitivity when AML was 
treated with ibrutinib in combination with either drug (Rushworth et al., 
2014). The SDF-1α/CXCR4 axis is established in AML as well as other cell 
types but only a few studies have shown participation of BTK in this 
pathway. BTK activation has been reported in acute myeloid leukaemia 
after AML was treated with SDF-1α which increased p-BTK detected via 
CXCR4 receptor stimulation. The downstream cellular events of SDF-
1α/CXCR4 pathway activation are affected by BTK inhibition. AML cells 
showed reduced migration toward SDF-1α in BTK knockdown AML cells 
(Zaitseva et al., 2014). Interference of the SDF-1α/CXCR4 pathway by 
inhibiting CXCR4 receptor with an inhibitor diminished AML cells survival 
and migration. Therefore, this pathway appears important in AML and may 
be one of the candidate pathways for therapeutic development to treat this 
cancer much better than the relatively poor options presently available.  
 
As we proved in the previous chapter that BTK expression is significant in 
AML, and BTK may be a potential drug target in AML, a better 
understanding of any role for BTK in the SDF-1α/CXCR4 pathway may be 
ripe for beneficial therapeutic development. This part of the thesis aims to 
investigate any participation that BTK may have in SDF-1α/CXCR4 
pathway and responses in AML and CLL human leukaemias. 
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4.2 Results 
In this chapter, we aim to identify whether BTK play any role in the SDF-
1α/CXCR4 signalling pathway in our AML and CLL model systems.  
 
4.2.1 Optimization of phosphorylated BTK activation after 100 ng/mL 
SDF-1α treatment 
The activation of phosphorylated BTK was examined after CXCR4 
receptor engagement by its ligand, SDF-1α/CXCL12, and whether BTK 
may be a putative pathway to exploit via CXCR4 pathway signalling. 
Phosphorylation of BTK was investigated after 100 ng/mL SDF-1α 
treatment. We initially optimized cell treatment with 100 ng/mL SDF-1α for 
10 min in some of the cell lines, then examined p-BTK and p-ERK protein 
levels downstream, measured by Western blotting in order to prove that 
this signal is transduced through BTK.  
 
Using THP-1 and Jeko-1 cell lines as AML and CLL representative models 
respectively, treatments were 100 ng/mL SDF-1α for 10 min or BCR cross-
linking assay for 15 min, by way of a positive control for p-BTK activation 
in B cells. In the BCR cross-linking assay, human IgM was used as a BCR 
receptor stimulus and donkey IgG was used as a control agent. 
Phosphorylation of BTK and ERK was not elevated by 100 ng/mL SDF-1α 
after 10 min treatment in both THP-1 and JEKO-1 while activation of p-
ERK was obviously detected after BCR cross-linking in Jeko-1 cells, but 
not THP-1 (Figure 4.1).  
 
Other AML cell lines (HL-60, U937, OCI-AML3, MV4-11 and Kasumi-1) 
were screened for p-BTK (Y223) and p-ERK activation. Cells were treated 
91 
 
for 10 min with 100 ng/mL SDF-1α and 1 μg/mL LPS acting as a positive 
control for p-ERK activation. In addition, p-BTK (Y551) was also examined 
after within the same cell treatments. Although p-BTK (Y551) antibody was 
not able to show much clear signal (even after much optimisation), the 
result can be interpreted as activation of both p-BTK (Y551) and p-BTK 
(Y223) not being obviously increased after SDF-1α treatment or LPS 
treatment. However, phosphorylation of ERK was more obviously 
increased in some of the cell lines comparing to untreated cells in both 
100 ng/mL SDF-1α and 1 μg/mL LPS treatments. A combination of 
variable levels of BTK among the AML cell lines, and often high basal p-
BTK levels in some cell lines, means that there is no clear activation by 
SDF-1α or LPS in any of the AML cell lines tested here.  Activation of p-
ERK by both SDF-1α and LPS was more apparent in U937, OCI-AML3, 
and less so in THP-1 cells.  Thus, the two ligands were successfully 
stimulating their receptors (CXCR4 and TLR4) but their ability to activate 
the BTK pathway is still to be determined, due once again to the limitations 
of the p-BTK antibodies available. 
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Figure 4.1 SDF-1α and BCR crosslinking stimulation on AML and CLL 
cell lines. 
THP-1 and JEKO-1 were stimulated by SDF-1α or anti-IgM antibody for 10 
min at 100 mg/mL and 10 ng/mL, respectively. BTK (anti-pBTK 1:1000) 
and ERK (anti-pERK 1:1000) phosphorylation were analysed by Western  
(A). Densitometric levels of phosphorylation were compared to total 
protein levels using ImageJ and plotted with GraphPad Prism (B).  
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Figure 4.2 Activation of phosphorylated BTK after 100 ng/µL SDF-1α 
treatment for 10 minutes. 
Human leukaemic cell lines were stimulated with 100ng/mL SDF-1α for 10 
min, water was used as vehicle control and 1 μg/mL LPS used as positive 
control for ERK, respectively. Protein was harvested and activation of 
interested proteins were determined by Western blot. 
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Figure 4.3 Densitometry of phosphorylated BTK Western blots. 
Phosphorylated protein band intensity was normalized with its total protein 
then each value was calculated in relative to untreated cells.  
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4.2.2 Expression of surface CXCR4 receptor on AML and CLL cell 
lines 
No increase in p-BTK was detected after 100 ng/mL SDF-1α stimulation 
(Figure 4.1 and 4.2), therefore, we needed to determine that the selected 
cell lines express CXCR4 receptor. In order to examine whether CXCR4 
was expressed on our leukaemia models, human leukaemia cell lines 
U937, THP-1, HL-60, MV4-11, OCI-AML3, Kasumi-1, and OCI-LY19 were 
subjected to CXCR4 receptor cell surface examination. Cells were stained 
with CXCR4-PE and IgG-PE antibodies for receptor staining and isotype 
controls according to the Materials and Methods chapter, section 2.5. The 
CXCR4 receptor staining (and isotype control) were examined by FACS 
analysis. As shown in Figure 4.3A, the expression of CXCR4 varied 
among cell lines, with OCI-AML3 cells showing the highest CXCR4 
expression levels among the AML and CLL cell lines, while CXCR4 
expression was the lowest in Kasumi-1 cells. CXCR4 expression levels on 
OCI-LY19 and THP-1 were the second and third highest respectively. 
Beside Kasumi-1, the expression of this receptor was similar in the 
remainder of the cell lines. The mean fluorescence index was plotted as 
demonstrated in Figure 4.3B. Interestingly, all cell lines expressed high 
amounts of CXCR4 receptor on their cell surface. Nevertheless, despite 
this high level of CXCR4 expression, and ability of SDF-1α to activate p-
ERK, elevation of BTK phosphorylation could not be detected after 100 
ng/mL SDF-1α treatment, as judged by our phospho-antibody Western 
blotting experiments. 
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Figure 4.4 Expression of surface CXCR4 receptor on AML and CLL. 
U937, THP-1, HL-60, OCI-AML3, MV4-11, Kasumi-1, and OCI-LY19 as 
indicated, were stained with CXCR4-PE according to the protocol outlined 
in the Materials and Methods chapter. CXCR4-PE and IgG-PE antibodies 
were used to detect CXCR4 and the isotype control, respectively. Cells 
were analysed for cell surface CXCR4 expression by FACS analysis (A). 
The mean fluorescence intensity was plotted (B). 
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4.2.3 BTK phosphorylation upon CXCR4 stimulation 
According to the FACS analyses, surface CXCR4 receptor was highly 
expressed on human leukaemic cell lines used in this study. Therefore, 
one possible reason that BTK phosphorylation could not be detected 
previously is the signalling from CXCR4 receptor occurs very rapidly and 
transiently, and we may not be able to detect p-BTK at only one specific 
time point. Therefore, all cell lines were screened for p-BTK activation 
upon 100 ng/mL SDF-1α treatment at 0, 1, 5, 10, 20, and 30 min time 
points, according to an improved protocol outlined in chapter II, section 
2.6. Expectedly, p-BTK signal was elevated after CXCR4 activation in 
U937, HL-60, OCI-AML3, MV4-11, and OCI-LY19. Phosphorylated BTK 
signal gradually increased then peaked at different time point in each of 
the different cell lines. U937 cells showed p-BTK gradually increased 
continuously until after 30 min treatment, while stimulation of p-BTK 
activation by SDF-1α peaked at 20 min, declining thereafter in treated 
OCI-AML3 and HL-60 cells. Phosphorylated BTK slightly increased from 1 
min and reached to maximum at 10 min treatment in OCI-LY19 CLL cells, 
with the apparent activation more rapid in CLL cells than AML cell lines. 
There was an unconvincing increase of p-BTK in MV4-11 cells, and little 
activation could not be seen in either THP-1 and Kasumi-1. Western 
blotting was performed four dependent experiments and densitometric 
analyses was shown in Figure 4.5 and 4.6.  
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Figure 4.5 Activation of phosphorylated BTK in response to SDF-1α. 
Human leukaemic cell lines were stimulated with 100 ng/mL of SDF-1α in 
time course manner form 0, 1, 5, 10, 20, and 30 min. Phosphorylated BTK 
was probed for BTK activation. Western blot was performed in 4 
dependent experiments, with this figure showing a representative blot.  
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Figure 4.6 Densitometry of Western blot from figure 4.5 analysed 
from the same experiment. 
Phosphorylated BTK band intensity was normalized with BTK and the 
value was calculated in relative to untreated cells. Data are analysed from 
four dependent repeat. 
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4.3 Discussion 
The aim of this chapter was to identify whether BTK was activated as a 
downstream target of SDF-1α/CXCR4 signalling pathway in human 
leukaemia AML and CLL subtypes.  We hypothesized that BTK activation 
was downstream of activated CXCR4 receptor in AML. 
 
In order to prove the hypothesis that BTK is a downstream signalling 
protein of this pathway in AML and CLL, phosphorylation of BTK was 
investigated after 100 ng/mL SDF-1α treatment. In earlier results, p-BTK 
was examined after 10 min of 100 ng/mL SDF-1α treatment and the result 
showed similarity of p-BTK level in untreated cells and 100 ng/mL SDF-1α 
treated cells. Moreover, activation of p-ERK which is downstream of BTK 
is not obviously increased after 100 ng/mL SDF-1α treatment. In this 
experiment, PLCγ2 phosphorylation should be determined as a proximal 
target of BTK. Thus, we wondered whether p-BTK was not obviously 
activated because either CXCR4 was not expressed on our model cells, or 
p-BTK activation was not observed at precise time point. 
 
The surface CXCR4 receptor was stained with CXCR4-PE antibody and 
the receptor density measured by FACS analyses. The results showed 
significant surface CXCR4 expression on human leukaemic cell lines that 
we used as models of AML and CLL. This is in agreement with other 
studies also showing CXCR4 expression on the cell surface of AML and 
CLL cell lines (Zaitseva et al., 2014, Burger et al., 1999). However, the 
receptor density on cell surface which is interpreted by mean fluorescence 
intensity was different for each cell line, thus CXCR4 expression is very 
much cell type-specific. Since CXCR4 is expressed on our models, BTK 
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phosphorylation should be detectable if we observe at the correct time 
point. Considering the cell treatment with time point aspect, there are two 
possible reasons that the elevation of p-BTK cannot be observed after 10 
min treatment with 100 ng/mL SDF-1α. The first reason is the selected 
time point is too long to detect the activation which the signal transduction 
may have already be declined after 10 min. In general, signal transduction 
occurs very shortly after ligand binding, then the signal is transduced to 
cascade downstream signalling molecules and trigger subsequent effects 
in the cell response to receptor stimulation. The second reason is high 
basal level of p-BTK in untreated cells, may prevent our one time point 
clearly showing any tendency of activation. Therefore, cells were treated 
with 100 ng/mL SDF-1α in time course in order to detect activation of BTK, 
covering both earlier and later time points. 
 
Extending our time points for analysis, showed conclusively, that SDF-1α-
stimulated BTK activation in U937, HL-60, OCI-AML3, and OCI-LY19 while 
activation may not change in MV4-11, THP-1, and Kasumi-1. MV4-11 is a 
FLT3-ITD mutation-containing cell line, with p-BTK being highly expressed 
at steady state basal levels, therefore we possibly cannot observe p-BTK 
activation above the high basal levels already present (Pillinger et al., 
2015). However, BTK should be involved in the SDF-1α (CXCL12)/CXCR4 
pathway since pertussis toxin inhibits SDF-1α-induced p-BTK activation in 
MV4-11 cells (Zaitseva et al., 2014). Similarly, p-BTK does not change in 
THP-1 cells as well. As shown in other studies, BTK inhibition does not 
affect THP-1 cell survival, therefore, BTK may not play any role in this cell 
line (Rushworth et al., 2014). Nevertheless, BTK has been reportedly 
involved in another pathway including the Toll-like receptor 4 (TLR4) 
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pathway, where 1 g LPS activates p-BTK after 5 min treatment in THP-1 
cells (Jefferies et al., 2003). Kasumi-1 cells expresses low levels of both 
BTK and ERK comparing to the other cell lines. Interestingly, Kasumi-1 
shows high expression of CXCR4 in the cell surface in another study 
(Zepeda-Moreno et al., 2012), while our findings indicated CXCR4 
expression was lowest in Kasumi-1 cells among other cell types. 
Therefore, Kasumi-1 may not be a good system when testing chemokine 
responses. In addition, we have experienced issues whereby Kasumi-1 
cells stop growing in culture, to give errant findings in other experiments 
too. 
 
This chapter conclude that AML and CLL cell lines express CXCR4 
receptor, and that BTK may be involved in signalling in the SDF-
1α/CXCR4 signalling in AML and CLL cell lines. 
 
  
103 
 
 
 
Chapter V 
 
 
The effect of Gα12 and Gα13 
knockdown on SDF-1α/CXCR4 
signalling in AML and CLL  
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5.1 Introduction  
Lentiviruses are a group of viruses in Retroviridae family. The Retrovirus 
genus group of viruses can infect a wide range of host cells including 
proliferative cells and non-proliferative cells alike, including hematopoietic 
cells (Sakuma et al., 2012, Manjunath et al., 2009). Lentivirus technology 
is a transgene delivery tool that takes advantage of lentivirus properties, 
where the expression of the transgene is a very long-term expression 
system, due to the transgene being integrated into the transduced cell’s 
genomic DNA after transfection. Since, lentivirus vectors are constructed 
and based upon HIV-1 virus, the safety issues surrounding the use of this 
vector in experimental protocols has to be of concern.  By separating the 
viral genes encoding viral structure and protein machinery for integration, 
into several plasmids, and allowing the virus to infect host cells only once, 
the safety is improved.  In addition, lentiviral vectors are also modified to 
increase the opportunity to infect wide range of host cells, making them 
more useful for cells that are able to be infected. In this study, we used 
third generation lentivirus delivery systems to infect Gα12- and Gα13-
targeted shRNA into human leukaemia cell lines, in order to identify 
whether Gα12 or Gα13 proteins participate in the interaction of SDF-
1α/CXCR4 and its signalling towards BTK.  
 
CXCR4 is a seven transmembrane G-protein-coupled receptor (GPCR) 
that transduces the signal from SDF-1α through to G protein subunits and 
activates sequential downstream signalling pathway effects. In steady 
state, G proteins cooperate with CXCR4 receptor in the form of 
heterotrimeric multimers comprising of the α, and βγ subunits.  When the 
G-protein α subunit is GDP-bound form, it is complexed with its 
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corresponding βγ dimer subunit and held in check. When the GPCR 
receptor is activated, GDP exchanges to the higher energy GTP and the 
Gα subunit becomes switched to an activated form through a 
conformational change that allows dissociation from its βγ subunit.  The α 
subunit is no longer held in check, and is free to activate downstream 
processes. 
 
In this chapter, we focus on Gα subunits which are divided into four main 
families, namely, Gαs, Gαi/o, Gαq/11, and Gα12/13, based on similarity of 
amino acid sequences (Hepler and Gilman, 1992, Simon et al., 1991). 
Different Gα subunit families contributes to distinct G-protein-coupled 
receptor (GPCR) actions and transduces the signal to different 
downstream effectors (Rubin, 2009). In general, CXCR4 receptor is 
thought to couple with Gαi family members, but it has been reported that 
CXCR4 may also transduce the SDF-1α signal to a different family of Gα 
subunits (Maghazachi, 1997, Rubin, 2009). In this study, we focus on the 
Gα12 family which are comprised of Gα12 and Gα13, which are thought to  
modulate Rho monomeric G-protein, cytoskeletal remodeling and some 
tyrosine kinase-induced migrations. Moreover, Gα12 is reported as a BTK 
TH/PH domain binding protein and Gα13 contributes towards CXCR4 
receptor and transduction of the signal to Rho in T cells and breast cancer 
(Jiang et al., 1998, Yagi et al., 2011, Tan et al., 2006). In acute leukaemia, 
CXCR4 transduces the signal from SDF-1α to Gαi, with BTK reportedly 
involved in this pathway’s control of migration (Zaitseva et al., 2014). 
Therefore, this chapter aims to identify in AML and CLL whether Gα12 or 
Gα13 family members cooperates with CXCR4 receptor and its activation 
of BTK.  
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5.2 Results 
5.2.1 Gα12 and Gα13 expression in different cell lines 
To understand the effect of Gα12 family knockdown in AML and CLL, 
expression of these two Gα proteins were screened in different human 
leukaemia cell lines. The expression of G protein alpha subunit of the Gα12 
family was investigated on U937, HL-60, OCI-AML3, OCI-LY19, and 
HEK293T. As shown in Figure 5.1, all human leukeamic cell lines and 
HEK293T cells expressed Gα12 and Gα13 even though the expression 
level of these Gα proteins was different among each cell line. The 
difference between these two Gα units is not only the expression levels 
seen in each cell line, but also the relative abundance of Gα12 and Gα13 in 
each cell. The required amount of total protein measured is different for 
Gα12 and Gα13, where 10 μg was needed for Gα12 detection, whilst Gα13 
needed use of approximately 20-40 μg of protein in order for it to be 
detected in these experiments. Therefore, Gα12 protein is more plentiful 
than Gα13 in our cellular models. The human monocyte cell line, U937, 
showed the highest expression of both Gα12 and Gα13 among these cells. 
On the other hand, Gα12 and Gα13 showed the lowest expression in HL-60 
cells, especially Gα13 which was only marginally detectable in this cell. The 
expression was similar in OCI-AML3, OCI-LY19, and HEK293T cells. 
Since these experiments were performed to choose a representative cell 
line for the Gα12/Gα13 knockdown experiment, we chose OCI-AML3 and 
OCI-LY19 cell lines are the best candidates among for such studies. 
Furthermore, both Gα proteins were detected in HEK293T cells, so this 
cell can also be used for the plasmid transfection in other experiments.   
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Figure 5.1 Expression of Gα12 and Gα13 in different cell lines. 
Human leukaemic cells and HEK293T cell had protein extracted and 
analysed by Western blotting. Ten microgram protein was loaded for Gα12 
and 20 to 40 μg protein was required for Gα13. Membranes were probed 
with Gα12 (1:500) and Gα13 (1:200) antibodies to observe basal expression 
of these two proteins.   
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5.2.2 Gα12 and Gα13 knockdown screening in HEK293T 
HEK293T is a suitable model for mammalian cell transfection, so we 
screened for the knockdown efficiency of each Gα12- and Gα13-targeted 
shRNA plasmid on this cell, so as to evaluate the efficiency of each 
plasmid before shRNA transduction with lentivirus in the human leukaemia 
cells. Five plasmids for each Gα12 and Gα13 (including scramble as non-
targeting control) were transfected into HEK293T separately according to 
the protocols outlined in the Materials and Methods chapter. The 
transfected HEK293T was incubated under cell culture conditions for 3 
days before protein was extracted and Western blotting performed to 
investigate the knockdown efficiency of each of the shRNA plasmids. The 
results showed the Gα12 knockdown efficiency was not apparently different 
among the five shRNA plasmids, with only E6 and E7 showing 
approximately 50% knockdown efficiency compared to the non-transfected 
control cells. The similarity for Gα13-targeted shRNA plasmid was 
observed with all clones showing similar knockdown efficiency (see Figure 
5.2). However, knockdown efficiency in HEK293T may differ from human 
leukaemic cells, therefore the shRNA plasmid clone E6 and clone C10 
were chosen to make Lentivirus containing Gα12- and Gα13-targeted 
shRNAs, respectively to be used in OCI-AML3 and OCI-LY19 transduction 
experiments.  
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Figure 5.2 Knockdown efficiency of Gα12 and Gα13 targeted shRNA 
plasmids in HEK293T. 
HEK293T was transfected with different Gα12- or Gα13-targeted shRNA 
plasmids. Protein lysate was prepared after 3 days of transfection. 
Western blotting shown in Figure A, with densitometry shown in Figure B. 
The bar graph showed Gα12 or Gα13 protein band intensity normalized to 
β-actin, plus the knockdown efficiency being compared to non-transfected 
(no plasmid) band densities.   
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5.2.3 Gα12 and Gα13 knockdown efficiency on OCI-AML3 and OCI-
LY19  
As we aim to investigate whether Gα12 family G-proteins engage with the 
signal transduction from the CXCR4 receptor and its interaction with BTK 
on AML and CLL cells, Gα12 or Gα13 were knocked down as above and the 
functional assays were examined on the Gα12 and Gα13 knockdown cells. 
Since there are well known difficulties associated with efficient transfection 
or infection in hematopoietic cells, our lentivirus delivery system was used 
as a tool for delivering Gα12- and Gα13-targeted shRNA plasmids into 
human leukaemic cells. The selected shRNA plasmids from the previous 
experiment, which are E6 and C10, were transfected into HEK293T with 
the third generation lentivirus plasmid to produce Gα12- or Gα13-targeted 
shRNA contained lentivirus particles. OCI-AML3 and OCI-LY19 were 
transduced with these lentivirus plasmids containing appropriate shRNA 
sequences, as described in the Methods chapter.  The transduced cells 
were selected by culturing for 6 days in the presence of 2-4 μg/mL 
puromycin as a selective pressure. The surviving cells were collected and 
their protein expression probed for Gα12 or Gα13 protein.  As shown in 
Figure 5.3, the expression of both Gα12 and Gα13 from transduced cells 
after puromycin selection, is markedly lower than expression in wild-type 
and scrambled control cells, with knockdown efficiency being improved by 
the puromycin selection process, compared to the non-puromycin-selected 
population. Therefore, both Gα12 and Gα13 were successfully knocked 
down.  Gα13 shRNA knockdown efficiency is greater than Gα12 shRNA-
mediated knockdown as Gα13 transfected cells were seen to be almost 
completely deplete the G-protein subunit. However, this result is 
consistent with previous experiments showing Gα13 being less abundant 
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than Gα12 in our cells, meaning that this protein may be easier to 
knockdown than Gα12 protein in our AML and CLL cells. The transduced 
cells were reselected with 4 μg/mL puromycin for 6 days, then expression 
level of Gα12 and Gα13 were checked regularly, as shown in Figure 5.3B. 
The effect of Gα12 or Gα13 depletion was assessed in further 
experimentation.  
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Figure 5.3 Gα12- and Gα13-targeted shRNA transduction into human 
leukaemic cell lines. 
Lentiviruses containing Gα12- or Gα13-targeted shRNA were transduced 
into OCI-AML3 and OCI-LY19 by the spinoculum Method. The transduced 
cells were cultured under 2-4 μg/mL puromycin for 6 days.  Thereafter, the 
surviving cells were examined for Gα12 or Gα13 knockdown efficiency 
(Figure A). The knockdown cells were further selected with puromycin 
culture, and the cell population checked regularly for knockdown of Gα12 
and Gα13 protein expression (Figure B). 
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Figure 5.3 contd/. Gα12- and Gα13-targeted shRNA transduction into 
human leukaemic cell lines. 
Lentiviruses containing Gα12- or Gα13-targeted shRNA were transduced 
into OCI-AML3 and OCI-LY19 by the spinoculum Method. The transduced 
cells were cultured under 2-4 μg/mL puromycin for 6 days.  Thereafter, the 
surviving cells were examined for Gα12 or Gα13 knockdown efficiency 
(Figure A). The knockdown cells were further selected with puromycin 
culture, and the cell population checked regularly for knockdown of Gα12 
and Gα13 protein expression (Figure B). 
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5.2.4 The effect of Gα12 and Gα13 on the SDF-1α/CXCR4 signalling 
pathway 
To assess whether Gα12 or Gα13 played a role in the SDF-1α/CXCR4-
mediated stimulation of BTK, we used the knockdown cells to judge any 
change in agonist stimulated cellular responses. BTK was phosphorylated 
after 100 ng/mL SDF-1α stimulation as shown in the previous chapter. As 
we hypothesize that Gα12 or Gα13 could participate with the CXCR4 
receptor and transduced signal to activate BTK, therefore Gα12 family 
knockdown cells were investigated for BTK activation by observing p-BTK 
and other phosphorylated proteins by Western blotting in SDF-1α/CXCR4-
stimulated time courses. As shown in Figure 5.4, p-BTK was not elevated 
after 100 ng/mL SDF-1α treatment in the time courses in both OCI-AML3 
and OCI-LY19. The phosphorylation of ERK 1/2 was also unchanged after 
SDF-1α/CXCR4 treatment in OCI-AML3 cells, while p-ERK was slightly 
changed in OCI-LY19. Given the disappointing stimulations that we 
expected and didn’t observe, we tried to minimize the basal stimulatory 
levels seen in these cells under test. These cells were serum-starved in 
serum-free RPMI overnight before performing similar experiments.  We 
suspected that serum-starvation may quiesce these cells and affect their 
basal expression of the phosphorylated kinases. The OCI-AML3 WT was 
used as a representative model to prove this. OCI-AML3 cells were plated 
overnight with different FBS concentrations, but our results showed that 
starvation did not have the desired effect on phosphorylation, since p-BTK 
and p-PLCγ2 (a kinase normally downstream of BTK activation) 
expression was high at 0 min under every FBS condition tested. Once 
again, our frustration with the p-BTK antisera led us to not have conclusive 
SDF-1α/CXCR4-stimualted BTK activation. Therefore, we used another 
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assay to test the interaction between the CXCR4 receptor and Gα12, Gα13, 
with BTK, to assess the effectiveness of Gα12 and Gα13 knockdown in 
these cells.  
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Figure 5.4 The effect of Gα12 and Gα13 knockdown on the SDF-
1α/CXCR4 signalling pathway. 
OCI-AML3 and OCI-LY19, wild-type (WT) cells were stimulated with 100 
ng/mL SDF-1α in the indicated time course. Phosphorylated BTK and p-
ERK1/2 were examined by Western blotting (Figure A). The effect of 
starvation on phosphorylated kinase expression was examined after 100 
ng/mL SDF-1α treatment, as shown in Figure B.   
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5.2.4 Gα12 and Gα13 are not involved in AML and CLL survival after 
Ibrutinib treatment  
Pharmaceutical BTK inhibition by ibrutinib has been reported to reduce 
survival and inhibit proliferation of primary AML, showing an effect on 
survival of some AML lines, U937 and FLT3-ITD AML cells (Zaitseva et al., 
2014, Wu et al., 2016). As we aim to identify whether Gα12 and Gα13 
interacts with BTK, BTK itself has been reported as an important signalling 
protein for AML cell survival, therefore we tested this hypothesis by 
treating the OCI-AML3 and OCI-LY19 with ibrutinib at different 
concentrations for up to three days and subsequent cell death was 
analysed by annexin-V/PI staining and FACS analyses. Overall, the 
percentage of cell death was not obviously different in Gα12 and Gα13 
knockdown cells, compared to wild-type control cells of both OCI-AML3 
and OCI-LY19, as shown in Figure 5.5. CLL cells showed slightly more 
sensitivity towards ibrutinib-induced death than AML cells. However, OCI-
AML3 Gα12 knockdown-mutant cells showed more ibrutinib-mediated cell 
death than wild-type or Gα13 knockdown cells. Surprisingly, there was less 
than 50 percent of cells that died after 2.5% DMSO treatment which we 
used as a positive control for our cell death experiments. These graphs 
were calculated from two independent samples of OCI-LY19 while OCI-
AML3 was performed once due to problems with cell contamination 
around the times of these experiments. What we can conclude from these 
series of experiments is that there is no dramatic ibrutinib-induced cell 
death in AML or CLL cells at any ibrutinib concentration, plus the effects of 
Gα12 or Gα13 protein family knockdown seems to not have any major effect 
on what minor cell survival changes that may be observable. 
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Figure 5.5 The effect of Gα12 and Gα13 on cell survival after ibrutinib 
treatment. 
OCI-AML3 and OCI-LY19, both wild-type (WT), Gα12 and Gα13 family 
knockdown cells were treated with various concentration of ibrutinib (0.1, 
0.5, 1, 5, and 10 μM) for 3 days. Ibrutinib-treated cells were then examined 
for cell death by annexin-V/PI staining and FACS analyses as described in 
the Materials and Methods chapter. The percentage of cell death was 
calculated by combining Annexin-V +ve/PI -ve, Annexin-V +ve/PI +ve, and 
Annexin V -ve/PI +ve cells. OCI-AML3 assessment from one experiment, 
with OCI-LY19 results averaged from two independent experiments.  
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5.2.5 Optimisation of the migration assay protocol 
The CXCR4 is a G-protein-coupled receptor that controls cell migration 
toward SDF-1α. We aim to identify whether Gα12 and Gα13 coupled to the 
CXCR4 receptor. Therefore, migration assays were performed to 
investigate the effect of Gα12 and Gα13 knockdown on migration ability 
toward the SDF-1α chemokine. In the initial experiments, several protocols 
for the migration assays were not stated in Materials and Method chapter, 
due to there being very poor apparent migration in response to ligand and 
low signal-noise ratio; hence the need for optimisation of this assay to 
determine the most suitable protocol for our cell lines tested here. 
 
First, we optimized cell number and amount of FBS in RPMI that befits this 
assay. CellTracker Green CMFDA Dye and fluorescence microscopy were 
used to optimize the measurement of migration. OCI-AML3 wild-type and 
OCI-LY19 wild-type cells (1 x 105, 2.5 x 105, and 5 x 105 cells/0.6 mL) 
were incubated with 10 μM CellTracker Green CMFDA Dye for 30 min, 
then cells were washed with media to remove excess dye and 
resuspended with either 1% FBS RPMI or serum-free RPMI. The indicated 
amount of OCI-AML3 and OCI-LY19 cells were seeded on 8 μm pore-
diameter transwell inserts and placed in a 24-well plate containing 1% 
FBS RPMI or serum-free RPMI. Cells were allowed to migrate for 3 h 
under cell culture conditions then the migrated cells were counted under a 
fluorescent microscope. Results showed that 2.5 x 105 cells and assay 
performed with 1% FBS RPMI were the best conditions for a more 
successful migration assay, as shown in Figure 5.6A.  However, OCI-LY19 
migrated cells could not be counted due to there being too many cells 
remaining in the bottom of the chamber, migrating without any SDF-1α 
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treatment (data was not shown). This may be due to the smaller cell size 
for CLL cells than AML cells, thereby allowing CLL cells to diffuse through 
the pores rather than it be a more active migratory process. For this 
reason, the effect of Gα12 and Gα13 knockdown was examined only on the 
OCI-AML3 cells.  
 
Since we struggled with reproducibility after migration assay were 
performed (n = 2) showing different results as seen in Figure 5.7A, we 
developed a secondary protocol. In this next protocol, the cell density, cell 
staining, and the incubation time were the same as previously measured, 
but the migratory cells were detected instead by a microplate reader rather 
than counting them under a fluorescence microscope. The results 
revealed that untreated and 100 ng/mL SDF-1α treatment conditions were 
not apparently different in the amount of migrated cells observed, even 
though cells obviously migrated towards the 100 ng/mL SDF-1α stimulus 
compared to untreated cells (as measured when the bottom chamber was 
observed under light microscopy before migrated cells were sampled, and 
measured by fluorescence microplate reader) as shown in Figure 5.7B. In 
this case, we think the microplate reader is not a sufficiently good 
detection system for this migration assay, similar to counting cells by 
fluorescence microscope, where the signal strength isn’t strong enough to 
give sufficient signal-noise ratio to enable adequate quantification. 
 
Lastly, OCI-AML3 wild-type cells were used for the migration assay 
optimisation. OCI-AML3 cells were resuspended with 1% FBS at 2.5 x 105 
cells (0.6 mL) density then seeded into a 8 μm transwell insert and placed 
on a 24-well culture plate containing 1% FBS RPMI (untreated control) or 
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various concentrations of SDF-1α (100 ng/mL, 200 ng/mL, and 400 ng/mL) 
in 1% FBS RPMI. 10% FBS RPMI treatment was used as a migration 
positive control stimulus. Cells were allowed to migrate toward SDF-1α for 
3 h and 4 h under cell culture conditions. Migrated cells were counted 
under a light microscope with trypan blue staining. Results revealed that 
200 ng/mL SDF-1α was the optimal concentration to induce migration of 
OCI-AML3 cells when they were incubated with chemokine for 4 h (Figure 
5.6B). Therefore, 200 ng/mL SDF-1α-induced cell migration and 4 h 
incubation time are good conditions for this migration assay.  This protocol 
was applied to the remaining migration assay experiments, as outlined in 
the Materials and Methods chapter. 
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Figure 5.6 Migration assay optimization with OCI-AML3 wild-type 
cells. 
Different cell densities of OCI-AML3 cells as indicated were seeded onto 8 
μm transwell inserts to determine optimal cell number and FBS 
concentration for a migration assay. Figure A, CellTracker Green CMFDA 
Dye was used to stain cells, with migrated cells counted by fluorescence 
microscopy after 3 h incubation with 100 ng/mL SDF-1α in the bottom 
chamber (RPMI ± 1% FBS). Figure B, various concentration of SDF-1α 
and incubation times as indicated are shown in Figure B, with migrated 
cells being counted with trypan blue exclusion staining.  
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Figure 5.7 The effect of Gα12 and Gα13 knockdown on migration 
toward SDF-1α. 
OCI-AML3 wild-type and Gα12 or Gα13 subtype knockdown cells were 
incubated with CellTracker Green CMFDA Dye for 30 min and allowed to 
migrate towards 100 ng/mL SDF-1α for 3 h. Migrated cells were counted 
by fluorescence microscopy (A) or the fluorescence intensity measured at 
492/517 nm excitation/emission spectra (B). These experiments represent 
the average of two independent experiments for each method tested.  
  
124 
 
5.2.6 Gα12 and Gα13 are important for OCI-AML3 migration towards 
SDF-1α via its CXCR4 receptor.  
Since Gαi has been already been identified by another research group to 
engage with the CXCR4 receptor in leukaemia cells, it has been reported 
that other families of Gα have the potential to be an effector molecule of 
this receptor (Tan et al., 2006, Zaitseva et al., 2014). Therefore, we aimed 
to identify whether Gα12 and Gα13 transduce signalling through CXCR4 in 
OCI-AML3 cells, with the migration assay being used as a functional 
assay to prove this hypothesis. OCI-AML3 wild-type cells and Gα12 and 
Gα13 knockdown cells were permitted to migrate towards 200 ng/ml of 
SDF-1α for 4 h as described. The migrated cells being counted in 
triplicate. As shown in Figure 5.8, the fold change of migrated cells from 
each G-protein knockdown cell were compared to wild-type (WT) cells. 
SDF-1α stimulation was apparent in each of the wild-type, Gα12- Gα13-
knockdown cells (P < 0.01 (**), n = 8). The Gα12 and Gα13 knockdown 
appeared to suppress this agonist CXCR4-mediated migration.  However, 
although there was inhibition in the Gα12 knockdown cells, with the 
inhibition seen being statistically significant (P < 0.05 (*), n = 8), the 
inhibition of SDF-1α-stimulated migration in Gα13 knockdown cells was 
equally statistically significant (P < 0.05 (*), n = 8)(see Figure  5.8).  
Migratory ability was seen when 10% FBS was the stimulus (P < 0.05 (*)).  
Interestingly, all three cell variants were unaffected by Gα12 or Gα13 
knockdown when migrating towards the 10% FBS stimulus, unlike when 
migrating towards a SDF-1α stimulus, which is impeded by G-protein 
knockdown. Therefore, Gα12 and Gα13 can both be seen to be CXCR4-
linked, with both partially controlling migration towards SDF-1α in OCI-
AML3 cells.  
  
125 
 
 
Figure 5.8 The effect of Gα12 and Gα13 knockdown on chemotaxis 
towards 200 ng/mL SDF-1α.  
OCI-AML3 wild-type (WT) and Gα12 or Gα13 knockdown cells were 
incubated in a transwell migration chamber in the presence of 200 ng/mL 
SDF-1α or 10% FBS (positive control) present in the bottom chamber. 
Cells were incubated for 4 h then migrated cells were counted by trypan 
blue exclusion staining. These data represent the mean ± SD fold 
stimulation from 8 independent repeat experiments (n = 8). Student’s T-
test was used as a determination of the statistical significance between 
wild-type and each knockdown (KD) cell (P < 0.05 (*); P < 0.01 (**)). 
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5.2.7 The effect on migration of Gα12 subtype knockdown after 
ibrutinib treatment 
We aimed to identify whether BTK is downstream of Gα12 and Gα13 in the 
signal transduction capability of the CXCR4 receptor.  Therefore, migration 
towards SDF-1α was investigated after BTK inhibition by ibrutinib 
treatment. As shown in Figure 5.9A, p-BTK was successfully inhibited by 
ibrutinib from 100 nM to 10 μM after 2 h inhibitor treatment. Wild-type OCI-
AML3 cells and Gα12 and Gα13 knockdown cells were treated with the 
indicated concentrations of ibrutinib from previous Western blotting 
experiments (2 h preteated) before incubation with 200 ng/mL SDF-1α for 
a further 4 h. Migrated cells were counted by trypan blue staining. The 
results showed the amount of migrated cells did not significantly differ 
comparing untreated wild-type OCI-AML3 cells to Gα12 or Gα13 knockdown 
cells. Cell migration slightly reduced in Gα12 knockdown and scrambled 
control transduced cells when cells were treated with ibrutinib, on the other 
hand, migrated cells showed an increased in Gα13 knockdown cells even 
p-BTK was also inhibited by ibrutinib. These experiments were not 
conclusive as the effect of ibrutinib on migration (as seen previously in this 
chapter) is not consistent or significant – thus we are unable to conclude 
of any involvement of BTK in the migration of OCI-AML3 cells induced by 
SDF-1α.    
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Figure 5.9 The effect of BTK inhibition on migration toward 200 
ng/mL SDF-1α in Gα12 and Gα13 knockdown cells. 
OCI-AML3 wild-type (WT) and Gα12 or Gα13 knockdown cells were treated 
for 2 h with 1 nM - 10 M ibrutinib then incubated with 200 ng/mL SDF-1α 
for a further 4 h. Phosphorylation of BTK after ibrutinib treatment (A), or 
SDF-1α-induced migration (B) is shown (means ± SEM, n = 2).  
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5.2.8 The effect on cytokine production of Gα12 family knockdown 
cells after ibrutinib treatment  
To examine the effect of BTK inhibition on cytokine expression in Gα12/13 
family suppressed cells, OCI-AML3 wild-type, Gα12/Gα13 knockdown, and 
scramble control cells were seeded at 2.5 x 105 or 5 x 105 cells/0.6 mL 
density.  Cells were treated with different concentrations of Ibrutinib for 2 h 
then incubated with 200ng/mL SDF-1α for a further 4 h. Cellular RNA was 
extracted and mRNA converted to cDNA, before qPCR was performed to 
investigate the mRNA expression of several cytokines. This experiment 
was performed three times with slightly differing methodology. Data from 
each experiment was plot into wild type and knockdown cells separately. 
Overall, there was no obvious difference between untreated and treated 
cells in either wild-type or Gα12 and Gα13 knockdown cells, apart from IL-8 
(Figure 5.10A & F) and IL-12A (Figure 5.10D). As shown in Figure 5.10E 
and F, cells were treated with 20 ng/mL TNF-α stimulus to act as a control, 
however, we could not detect the expected increase in cytokine 
expression that normally occurs after TNF-α treatment. Therefore, these 
experiments were not conclusive and are probably more indicative of the 
high basal activities of signalling and mRNA production that are often 
associated with these type of leukemia cancer cells.  Further optimisation 
work is needed to improve the preconditioning of these cells to allow more 
reproducible and reliable signalling findings.  
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Figure 5.10 The effect of Gα12 and Gα13 on SDF-1α induced cytokines 
production in ibrutinib treated cells. 
OCI-AML3 WT and Gα12 family knockdown were treated with various 
concentration of ibrutinib (0.1, 1, and 10 μM) for 2 hr then continually 
incubated with 200 ng/mL SDF-1α for 4 hr. The cytokines expression was 
examined by qPCR. Figure A-F represent different experiment which 
slightly different in each. Figure A-B, WT (A) and Knockdown (B) cells 
were treated with three concentrations of Ibrutinib. Figure C-D, WT (C) and 
knockdown (D) cells were treated with 1 μM Ibrutinib and H2O was used 
for vehicle control. Figure E-F, WT (E) and knockdown (F) cells were 
treated with the same condition with experiment in figure C and D and 
TNF-α treated cells were used as positive control. 
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Figure 5.10 contd/ The effect of Gα12 and Gα13 on SDF-1α induced 
cytokines production in ibrutinib treated cells. 
OCI-AML3 WT and Gα12 family knockdown were treated with various 
concentration of ibrutinib (0.1, 1, and 10 μM) for 2 hr then continually 
incubated with 200 ng/mL SDF-1α for 4 hr. The cytokines expression was 
examined by qPCR. Figure A-F represent different experiment which 
slightly different in each. Figure A-B, WT (A) and Knockdown (B) cells 
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5.3 Discussion 
The main objective of this study was identifying whether Gα12 and Gα13 
linked with the CXCR4 receptor in AML and CLL leukaemia subtypes. The 
OCI-AML3 and OCI-LY19 were transfected with lentivirus containing Gα12 
or Gα13 targeted shRNAs then the effect of Gα12 or Gα13 knockdown was 
investigated to answer this research question.  
 
The basal expression of these two Gα proteins in Gα12/13 subtype was 
examined in various cell lines, including U937, HL-60, OCI-AML3, OCI-
LY19, and HEK293T. The differences in expression levels was observed 
in each cell line with the highest expression being found in U937 whilst 
HL-60 showing the lowest expression of Gα12 and Gα13 among cells 
tested. Interesting, we found the relative expression of Gα12 and Gα13 was 
obviously different which can imply that these two proteins in the Gα12 
family have different abundance in each cell line for an unknown 
physiological reason. These experimental findings are supported by the 
studies of others (Tan et al., 2006).   
 
Lentivirus-based shRNA transfection was used to suppress Gα12 and Gα13 
mRNA expression in OCI-AML3 and OCI-LY19. Experiments were 
performed to screen knockdown efficiency of Gα12 and Gα13 targeted 
shRNA in HEK293T cells. Results revealed similar knockdown efficiency 
for each of the shRNA plasmids tested with only some of them showing 
approximately 50% knockdown for Gα12 but less than 50% for Gα13. The 
E6 and C10 shRNA plasmids which target Gα12 and Gα13 respectively 
were chosen to make lentivirus-containing shRNA plasmid in packaging 
HEK293T cells, then transduced into OCI-AML3 and OCI-LY19. After the 
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puromycin selection step, results revealed that the knockdown efficiency in 
leukaemia cell lines was better than HEK293T cells, especially Gα13-
targeted shRNA since only cells containing the integrated shRNA plasmid 
can survive and were enriched under the puromycin selection. 
 
The effects of Gα12 and Gα13 knockdown were investigated in OCI-AML3 
and OCI-LY19. We hypothesized that BTK is the downstream effector that 
receives a signal from Gα12 or Gα13 after CXCR4 receptor is stimulated. 
Therefore, BTK and ERK1/2 activation were examined after CXCR4 
receptor signalling pathway stimulation by SDF-1α. The phosphorylation of 
BTK and ERK1/2 were not elevated after 100 ng/mL SDF-1α treatment 
which showed that p-BTK was activated in SDF-1α treated OCI-AML3 
from the previous chapter. As OCI-AML3 and OCI-LY19 were serum-
starved overnight before performing experiment, thus the starvation step 
may affect cell stress and induced a higher basal background of 
phosphorylated protein. To investigate this suspected influence, OCI-
AML3 (chosen as a representative cell) were incubated overnight with 
serum-free RPMI, 1% FBS RPMI, and 10% FBS RPMI, then BTK and 
PLCγ2 phosphorylation observed after 100 ng/mL SDF-1α treatment. The 
result from Figure 5.4B revealed that starvation did not provoke a change 
in the basal levels of p-BTK and p-PLCγ2 since expression level of these 
two phosphorylated protein was not obviously different in each FBS 
concentration – the protein phosphorylation at 0 min from starved cells 
were as high as cells that were plated overnight in 10% FBS RPMI. 
Therefore, the high basal levels of these phosphorylated proteins may be 
generated by the cell itself and not an external factor. According to this 
experiment, we cannot interpret the effect of Gα12 or Gα13 suppression by 
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studying BTK activation, so we require other assays to investigate the 
relationship of the SDF-1α/CXCR4 pathway, Gα12 subtypes and BTK in 
AML and CLL leukaemia subtypes.    
 
The involvement of BTK has been reported on cell survival, so wild-type 
and Gα12 or Gα13 knockdown cells were examined for cell death 
responses after exposure to various concentrations of BTK inhibitor 
ibrutinib. Surprisingly, the percentage of dead cells was less than 50% 
after ibrutinib treatment fully for 72 h. However, OCI-AML3 seemed more 
sensitive to ibrutinib than OCI-LY19 cells since less than 20 percent of 
death cells was observed after ibrutinib treatment while OCI-AML3 
showed higher percent of death cells at the same concentration of 
ibrutinib. Therefore, Gα12 and Gα13 may not interact with BTK or they may 
interact with BTK but the interaction is not correlating or involving the cell 
survival response.  
 
The SDF-1α/CXCR4 signalling pathway controls cell motility and Gαi is 
reported to couple this receptor. However, it is possible that more than one 
family of Gα protein may participate in a G-protein-coupled receptors 
signalling (Rubin, 2009). Therefore, we aimed to identify Gα12 family 
members apart from Gαi proteins that have already been reported from 
several research groups. In order to examine the effect of Gα12 or Gα13 
knockdown on migration toward SDF-1α, the migration assay was 
optimized for the reliable result when we faced problems about detection, 
system limitations and reproducibility. Fluorescence dye was used as a 
first method when cells were stained with CellTracker Green CMFDA dye 
and migrated cells were counted under a fluorescence microscope. 
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Interestingly, OCI-LY19 migrated without SDF-1α induction. Even this cell 
line expresses CXCR4 receptor but this phenomenon may be caused by 
the cell type size characteristic as 8 μm transwell inserts appear too big for 
this cell line. However, we can set up the optimal cell number for migration 
assay of OCI-AML3 but unfortunately, we could not get reproducible data 
when the actual migration assay was performed. Fluorescence intensity 
was used as a second method to detect migrated cells. Results fluctuated 
between untreated and SDF-1α-treated in wild-type and Gα12 knockdown 
cells, and there were differences between untreated and SDF-1α treated 
cells in Gα13 knockdown and scramble control cells, as results were not 
correlated between the cells found at the bottom of the transwell chamber 
being observed under light microscopy or fluorescence microscopy 
measurements. There are some possible explanations that can explain 
these anomalous result. Firstly, there is a limitation of this measurement 
method that cannot detect fluorescence intensity when it was emitted from 
a small amount of cells because migrated cells were aliquoted into a small 
volume from 24-well plate to 96-well plate for measurement. Secondly, this 
detection method may be too variable from sample to sample so that data 
is not consistent enough to analyse reproducibly or accurately. We took 
advantage of the fact that we could observe cells under a microscope 
were actually seen to migrate toward SDF-1α, so trypan blue cell counting 
was used as the third method to measure cell migration. According to our 
results, OCI-AML3 showed a defect in migration toward SDF-1α when 
both Gα12 or Gα13 was knocked down compare to wild-type cells. However, 
Gα12 knockdown should have relatively more effect to inhibiting migration 
than Gα13 knockdown due to Gα13 protein being nearly fully suppressed in 
knockdown cells, but Gα12 protein knockdown is much less dramatic, but 
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there is still considerable inhibition of migration in these Gα12 knockdown 
cells. Therefore, this result implies that Gα12 or Gα13 both participate with 
the CXCR4 receptor to transduce its signal from its ligand to regulate cell 
motility. As migration did not completely reduce in either Gα12 or Gα13 
suppressed cells, there probably is another protein that helps carry this 
signal to downstream effectors.  This other protein could be Gαi which has 
already identified from other studies, or it is possible that other unknown 
pathways can control cell migration in these cell too (Tan et al., 2006, 
Zaitseva et al., 2014).  
 
This study we question that Gα12 or Gα13 also couples with CXCR4 and 
transduce the signal from CXCR4 receptor and induce BTK activation after 
SDF-1α stimulation. The coupling of Gα12/Gα13 with CXCR4 receptor we 
already identified from the previous experiments. Therefore, BTK was 
pharmacologically inhibited with ibrutinib and migration assay performed to 
examine whether BTK inhibition affects migration in wild-type or Gα12 or 
Gα13 OCI-AML3 cells. The p-BTK was successfully inhibited but the 
migration assay results were not convincing. These experiments were 
performed in wild-type OCI-AML3 and knockdown cells, where incubation 
with ibrutinib for 2 h then washing before SDF-1α treatment means that 
the washing steps between the two treatments may affect the cell 
migration such that the amount of cells at the beginning of the assay may 
not accurately relate to the migrated cells found at the end of experiment. 
In addition, p-BTK in OCI-AML3 cells has being high without any treatment 
as shown in previous experiment.  This is an ongoing difficulty to get better 
signalling information out of AML cells which naturally have very high 
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basal activities in many biochemical processes, making these cells highly 
active and highly drug-resistant. 
 
To consider the effect of Gα12 subtype knockdown and BTK inhibition on 
cytokine expression, wild-type OCI-AML3 and Gα12/Gα13 knockdown cells 
were treated with ibrutinib for 2 h and then continually incubated with 200 
ng/mL SDF-1α for 4 h, but instead of migration, the expression of 
cytokines was examined by qPCR. Wild-type and Gα12 subtype 
knockdown cells were treated with DMSO diluted ibrutinib but DMSO 
seems has an effect on cytokines mRNA expression as the amount of 
DMSO was higher than 2%, which is not good for cells stability. Therefore 
water was used as a diluent to minimize the effect of DMSO. The TNF-α 
was used as a positive control at 20ng/mL which should cause 
considerable induction of some cytokines particularly TNF-α itself (often a 
20-50 fold increase is expected). However, there was not much difference 
in cytokine expression between untreated and treated cells even in the 
positive control. Therefore, we cannot conclude the interaction between 
Gα12/13 subtypes and BTK, as this experimental approach needed further 
optimisation to gain more reliable and reproducible results.  
 
In summary, we can conclude that Gα12 or Gα13 subunits are coupled to 
the CXCR4 receptor to transduce its SDF-1α signal, and that both G-
protein subunits are involved in controlling AML cell migration processes.  
However, more needs to be done to gain more reliable results with these 
troublesome cells and better understand these signalling pathway in AML.  
  
141 
 
 
 
Chapter VI 
 
 
General Discussion 
  
142 
 
General Discussion and Conclusions 
This study comprises two main objectives in order to understand the role 
of BTK in different aspects of leukaemia. The first objective is investigation 
of BTK and p-BTK in the nucleus and cytoplasm of human leukaemia AML 
and CLL subtypes. The second objective is identification of whether Gα12 
and Gα13 couple with CXCR4 receptor and transduce signals to activate 
BTK and cellular response via BTK in AML and CLL leukaemia subtypes. 
 
Acute myeloid leukaemia and chronic lymphocytic leukaemia have a high 
incidence in the elderly. The standard treatment strategy of AML is to 
introduce the patient with high dosage of cytarabine and an anthracycline, 
usually daunorubicin. This treatment shows favourable outcomes for 
younger AML diagnosed patients while patients older than 65 suffer from 
high cytotoxicity side effects. Therefore, a new therapeutic strategy is 
needed to increase the favourable outcome for this group of patients. 
Ibrutinib is a BTK inhibitor used to treat CLL leukaemia and shows a good 
outcome for older patient. Interestingly, several studies reveal the 
influence of BTK in the pathophysiology of AML. Therefore, BTK may be a 
protein kinase with a vital role in AML as well as CLL and BTK can also be 
a potentially candidate drug target for AML treatment. Indeed, the potential 
of BTK to be a drug target for AML has been previously reported. The 
FLT3-ITD, mutation present in high percentages of relapsed AML patients, 
shows sensitivity to ibrutinib treatment in AML cell lines. Understanding 
the role of BTK in AML could provide relapsed AML patients with a new 
therapeutic strategy, the use of BTK inhibitors. 
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BTK is a non-receptor tyrosine kinase, which allows flexibility in cellular 
localization. Indeed, BTK is found in the cytoplasm, nucleus and plasma 
membrane. BTK phosphorylation may regulate compartmentalization as it 
is thought to allow translocation to different cell compartment to regulate 
function. This mechanism is not fully understood. BTK expression (BTK) 
and phosphorylation (p-BTK) was investigated, we looked at the 
cytoplasm and nuclear localization of BTK in AML and CLL cell lines to 
characterize changes in activation and expression levels in the cellular 
fractions. Additionally, we wanted to identify BTK binding partners and the 
role of BTK in nucleus. After optimizing the protocol to analyze the levels 
of BTK expression and phosphorylation, we found that BTK is not only 
expressed, but also activated by phosphorylation in both the cytoplasm 
and nucleus, of AML and CLL cell lines at basal levels. This finding is 
relevant to consolidate BTK as a target in AML. However, we need further 
experiments to understand the function of BTK and to explain the 
important of the nuclear localization and its function in nucleus. There are 
proposed models of BTK nuclear translocation and identification of 
putative BTK binding proteins, including transcription factor TFII-I, 
STAT5A, and Bright, however, the direct role of BTK in nucleus has not 
been established (Mohamed et al., 2000, Gustafsson et al., 2012, Novina 
et al., 1999, Mahajan et al., 2001, Rajaiya et al., 2005). 
 
BTK serves as a linker molecule that can be activated from several 
pathways and control diverse responses. The SDF-1α/CXCR4 axis also 
activates BTK and its downstream protein in B cells and B cell malignancy 
(de Gorter et al., 2007, de Rooij et al., 2012, Chang et al., 2013, Ponader 
et al., 2012, Hendriks et al., 2014).  The CXCR4 is G protein-coupled- 
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receptor which the pertussis toxin sensitive Gαi subunit has been reported 
to link with in most cells including AML (Zaitseva et al., 2014). SDF-
1α/CXCR4 plays a role in cell migration and metastasis in response to 
SDF-1α binding. In leukaemia and other cancers, CXCR4 and its ligand, 
SDF-1α, are main participants in the microenvironment which provides 
supportive survival signal and protects cancer cells from drug-induced 
apoptosis which leads to disease relapse. In addition, the SDF-1α/CXCR4 
pathway is not completely understood and the regulation may be cell type 
specific (Bruhl et al., 2003). The second aspect of this thesis, we were 
interested in SDF-1α/CXCR4 pathway in AML, particularly, the Gα subunit 
of the G-protein coupled receptor and its relationship with BTK. We 
targeted the Gα12 or Gα13 to study the SDF-1α induced cellular response 
in AML and CLL leukaemia subtypes. However, other Gα subtypes can 
also be coupled with CXCR4 leading to the same cellular activity through 
distinct downstream cascades, as shown in Jurkat T cells (Tan et al., 
2006). We have hypothesized that Gα12 subtypes receives signalling from 
CXCR4 receptor and activates BTK, leading to regulation of migration, 
gene expression, and cell survival  in response to SDF-1α in in AML and 
CLL. 
 
In order to understand the conveyance of signalling from CXCR4 to BTK 
after SDF-1α binding and to identify Gα12 subtypes that link to this 
receptor, human leukaemic cell lines were analyzed for expression levels 
of CXCR4 receptor. The result revealed that all cell lines used in this study 
express CXCR4 receptor. Moreover, BTK is phosphorylated after SDF-1α 
treatment in U937, HL-60, OCI-AML3, and OCI-LY19. Other studies also 
show BTK activation after SDF-1α treatment in different cell lines (Zaitseva 
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et al., 2014, de Gorter et al., 2007, Bam et al., 2013). The expression of 
Gα12 and Gα13 was examined in AML cell line, CLL cell line, and HEK293T 
where Gα12 showed higher protein expression than Gα13 while the 
abundance of these Gα subunits was vice versa in Jurkat T cells which 
mean the abundancy of Gα protein is cell type specific (Tan et al., 2006). 
The difference in basal expression level between Gα12 and Gα13 has been 
also reported  previously (Strathmann and Simon, 1991). In this study, we 
aim to fulfill the knowledge of SDF-1α/CXCR4 signalling pathway in 
human leukaemia, particularly the involvement of Gα subunit and 
downstream signalling. Even though CXCR4 links with Gαi but other Gα 
subtypes also has been reported to link with this receptor (Rubin, 2009, 
Tan et al., 2006, Maghazachi, 1997, Zaitseva et al., 2014). In addition to 
Gαi, we aim to identify the Gα12 subtypes whether Gα12 or Gα13 which 
belong to this family has a responsibility to transduce signal from CXCR4 
upon SDF-1α binding to activate downstream cascade in AML. Gα12 and 
Gα13 targeted shRNA were transduced into OCI-AML3 and OCI-LY19 to 
suppress Gα12 and Gα13 protein expression. The effect of Gα12 subtypes 
reduction was examined by migration assay, both OCI-AML3 wild-type 
(WT) and OCI-AML3 Gα12 subtypes knockdown were allowed migration in 
response to SDF-1α. Since OCI-LY19 migrated in absence of SDF-1α, 
OCI-LY19 was excluded from this study and the effect of Gα12 subtypes 
knockdown and other experiments were performed in OCI-AML3 only. The 
ability of SDF-1α to induce cell migration was investigated in Gα12 and 
Gα13 suppressed OCI-AML3 and the result reveals that cell migration was 
significantly reduced after Gα12 or Gα13 knockdown compared to wild-type 
(WT) and scramble transfected cells. In addition, migration was rescued in 
the presence of 10% FBS. This data suggests that either Gα12 or Gα13 
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participates in SDF-1α/CXCR4 signalling pathway. Interestingly, this result 
supports our hypothesis that more than one Gα subtype is involved in 
migration since the migration ability of knockdown cells did not completely 
reduce. Moreover, it is possible that SDF-1α binds not only to CXCR4 but 
CXCR7 too. In addition, CXCR7 was reported its expresses on AML can 
control cell migration (Melo et al., 2014, Kim et al., 2015). 
 
Since BTK has been reported several times as a regulator of cell migration 
in response to SDF-1α binding (Bam et al., 2013, de Gorter et al., 2007, 
de Rooij et al., 2012, Zaitseva et al., 2014), our data suggests BTK is a 
downstream molecule of either Gα12 or Gα13 in SDF-1α/CXCR4 signalling 
pathway for AML. To assess role of BTK in this pathway, we measured the 
pharmacological effect of the BTK specific inhibitor, ibrutinib, in the 
inhibition of BTK in Gα12 and Gα13 knockdown and wild-type (WT) cells by 
measuring downstream phosphorylation, cell survival, migration, and 
cytokine production. BTK is involved in cell survival and SDF-1α/CXCR4 
signalling provides survival support to cells in the bone marrow 
microenvironment, thus we hypothesize that Gα12 or Gα13 convey 
signalling to a downstream cascade to control cell survival mediated by 
BTK. To test this hypothesis, OCI-AML3 and OCI-LY19 both wild-type 
(WT) and Gα12 and Gα13 knockdown were exposed to increasing 
concentrations of ibrutinib for 3 days and cell death was examined by flow 
cytometry using  annexin V/PI staining for cell death. We found that BTK 
inhibition did not affect cell survival in wild-type and knockdown cells, in 
addition Gα12 and Gα13 knockdown does not have an effect on cell survival 
in OCI-AML3 and OCI-LY19 (Figure 5.5). Although some studies show 
BTK inhibition effect cell survival (Ponader et al., 2012, Nimmagadda et 
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al., 2017), our results suggests that no changes occur. However, there is 
study demonstrating only U937 sensitivity to Ibrutinib among four other cell 
lines, therefore, it is possible that BTK may not be involved in survival of 
OCI-AML3 and OCI-LY19 (Rushworth et al., 2014).  The role of BTK in cell 
migration in response to SDF-1α binding is also proposed for other cell 
lines (Zaitseva et al., 2014, Ponader et al., 2012). 
 
In this study, we also aimed to investigate the role of BTK in migration in 
Gα12/13-linked CXCR4 receptor toward SDF-1α in AML. Unfortunately, we 
cannot conclude the importance of BTK in Gα12/13-linked CXCR4 receptor 
in response to SDF-1α in AML cell lines from this study because the result 
is not reliable enough for interpretation. Focusing on OCI-AML3 wild-type 
(WT), fold change of migrated cells neither obviously increased nor 
decreased after SDF-1α and ibrutinib treatment even though knockdown 
cells showed slight changes in contrast with previous experiments where 
OCI-AML3 obviously migrated toward SDF-1α. It is possible that BTK can 
control migration and cooperate with Gα12 and Gα13 but we are limited to 
the assays used. It is possible that further optimization is required. 
 
Besides cell motility, SDF-1α/CXCR4 signalling also controls gene 
expression, especially genes involved in cell survival. We hypothesized 
that expression of genes that regulate cell growth will increase in response 
to SDF-1α/CXCR4 signalling in OCI-AML3 wild-type (WT) and Gα12 or 
Gα13 knockdown and these genes may under BTK regulation. In this study, 
cytokine encoded genes were chosen to investigate participation of BTK in 
gene expression after SDF-1α treatment. Result shows mRNA levels of 
cytokines were variable, therefore, we could not identify significant 
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changes. Because this experiment is very promising and optimization can 
be quite challenging, we suggest further optimization for accurate results. 
Notably, our positive control, TNF-α, expression remains unchanged when 
we expect massive upregulation of gene expression after SDF-1α 
treatment. We consider the inconclusive data because of experimental 
condition. Since, SDF-1α/CXCR4 controls cytokine encoded gene 
expression via NF-κB and BTK has been reported as an upstream 
regulator of NF-κB (Scupoli et al., 2008, Hendriks et al., 2014). 
 
In summary, this work reveals two significant findings. Phosphorylated 
BTK was found in nucleus, which suggests it is actively regulating proteins 
after nuclear translocation. In addition, CXCR4 can transduce signalling to 
Gα12 subtypes upon SDF-1α treatment and it is possibly controlling 
stimulation of cell motility. Overall, our data supports previously published 
data that BTK has an important function in AML and it could be a targeted 
for AML therapy. However, we cannot confidently prove the involvement of 
BTK in this pathway in AML leukaemia subtype. According to the results 
from this study, we proposed the summarize schematic of SDF-1α/CXCR4 
signalling pathway in OCI-AML3 as shown in figure 6.1. 
 
Perspectives on Future Work 
This study aims to understand role of BTK in nucleus and identify 
participation of BTK in SDF-1α/CXCR4 signalling pathway. Even though, 
this study reveals two main findings that BTK may have important 
functions in the nucleus and Gα12 subtypes and involved in signal 
transduction in SDF-1α/CXCR4 pathway. However, we still cannot explore 
the role of BTK in the nucleus and the importance of BTK in SDF-
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1α/CXCR4 signal transduction.  To completely understand role of BTK in 
nucleus, the nuclear localization and putative BTK binding partners should 
be investigated. BTK expression and phosphorylation will be examined in 
BTK wild-type (WT) and domain mutant and the putative BTK binding 
protein can be pull down compare between wild-type and domain mutant 
in both cytoplasmic and nuclear fraction. 
 
In order to complete the understanding of SDF-1α/CXCR4 axis and 
involvement of BTK in this pathway, the migration assay and cytokine 
production after ibrutinib treatment have to be optimized. In addition, the 
experiment should be performed with more AML cell line as well as patient 
sample in order to understand role of BTK in clinical situation.    
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Figure 6.1 Summary schematic of SDF-1α/CXCR4 signalling pathway 
in OCI-AML3. 
Results were concluded and proposed as a model of SDF-1α/CXCR4 
signal transduction in OCI-AML3. Once ligand binding, the signal is 
transduced from receptor to downstream molecule through Gαi or Gα12 
subclass. Then Gα subunit activates other proteins which BTK may be one 
of Gα12 subclass target and control migration, survival, or gene expression 
in response to SDF-1α. However, the participation of BTK in this pathway 
is still unclear and need further experiment to prove this hypothesis.  
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Appendix 
 
Figure A1 TATA binding protein antibody. 
Human leukaemic cells are fractionated and cytoplasmic and nuclear 
protein were prepared as describe in Materials and Methods. The TATA 
binding protein (TBP) was used as a nuclear marker to examine protein 
purity. The arrow indicates TBP expected size which is not major band in 
this blot (38 kDa). 
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Figure A2 Gα12- and Gα13- targeted siRNA transfection in HEK293T by 
using TransIT-mRNA transfection kit. 
Human embryonic kidney (HEK293T) was transfected with Gα12- or Gα13- 
targeted siRNA and incubated for 2 days. The transfected cells were 
performed protein extraction and Western blot as describe in the Materials 
and Methods section. 
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Figure A3 pLKO.1 plasmid for shRNA (Moffat et al., 2006). 
This figure represents the plasmid construct of Gα12- and Gα13- targeted 
shRNA plasmid that we used in this study. This figure is adapted from 
Moffat et al (Moffat et al., 2006)  DOI: 10.1016/j.cell.2006.01.040 
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Figure A4 Gα12- and Gα13- targeted short hairpin RNA plasmid 
screening. 
The Gα12- and Gα13- targeted shRNA were perform plasmid DNA 
extraction as describe in Materials and Methods. Plasmids were screened 
the present of puromycin resistance gene by primers in Table 1. 
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Gene hPGK Forward Puromycin Reverse Product 
size (bp) 
Tm 
Puromycin 
resistance  
GTGTTCCGCATTCT 
GCAAGC 
CCGGAATTCTCAGGC 
ACCGGG 
607 56 
 
Table A1 Primer for short hairpin screening. 
This table shows the primers used for puromycin resistance gene 
amplification. 
 
 
